Stellantis Reports Full Year 2025 Financial Results

Stellantis Reports Full Year 2025 Financial Results

Decisive Reset to Meet Customer Preferences
Focus on Strong Execution in 2026

  • Net revenues of
    €153.5 billion
    , down
    2%
    compared to 2024, mainly due to FX headwinds and also from H1 2025 net pricing declines
  • Net loss of
    €22.3 billion
    due to €25.4 billion of full year unusual charges,
    primarily reflects a strategic shift to put customer preferences and freedom-of-choice back at the heart of the Company’s plans
  • Adjusted operating loss

    (2)

    of
    €842 million
    with AOI margin

    (3)

    of
    (0.5)%
    , AOI negatively impacted by a number of specific items
  • Industrial free cash flows

    (4)

    were negative
    €4.5
    billion
  • H2 2025, the first full
    6 months
    of the renewed leadership team, saw improvements in revenue growth and I
    FCF

    (4)

    . Top-line growth was re-established with a 10% year-over-year increase in Net revenues. H2 2025 IFCF

    (4)

    of negative €1.5 billion represents approximately 50% improvement compared to H1 2025, and 73% improvement compared to H2 2024
  • Industrial available liquidity

    (9)

    was €46 billion at the end of 2025. To preserve a strong balance sheet the Board authorized the suspension of the 2026 dividend and the issuance of up to €5 billion of hybrid bonds
  • New product wave broadens market coverage with added white-space products and powertrain options across North America, Enlarged Europe, South America and Middle East & Africa targeting profitable growth opportunities
  • 2026 Financial Guidance Affirmed. Company expects to progressively improve Net revenues,
    AOI margin

    (3)

    and Industrial free cash flows

    (4)

    in 2026, and to see progressive improvements from H1 2026 to H2 2026
“Our 2025 full year results reflect the cost of over-estimating the pace of the energy transition and of the need to reset our business around our customers’ freedom to choose from the full range of electric, hybrid and internal combustion technologies.”

 

“In the second half of the year we began to see initial, positive signs of progress with the early results of our drive to improve quality, strong execution of the launches of our new product wave and a return to top line growth. In 2026 our focus will be on continuing to close the execution gaps of the past, adding further momentum to our return to profitable growth.

 

                                                                            Antonio Filosa, CEO

 
  2026 Dodge Charger SIXPACK – 2026 NA Car of the Year®

€ million / units million

 

  FY 2025   FY 2024   Change   H2 2025

 

  H2 2024

 

  Change

 

   

 

FY 2026 FINANCIAL GUIDANCE

 

Net revenues: Mid-Single Digit % Increase

 

AOI margin(3): Low-Single Digit %
                     
Industrial free cash flows(4): Improved Y-o-Y
(incl. €2B in 2026 payments related to H2 ’25 charges)

 

Expect Positive Industrial free cash flow(4) in 2027

             
I

F

R

S

 

 

 

Net revenues   153,508   156,878   (2)%   79,247   71,861   +10%  
Net profit/(loss)   (22,332)   5,520   n.m.   (20,076)   (127)   n.m.  
Diluted EPS   (7.75)   1.84   n.m.   (6.96)   (0.05)   n.m.  
Cash flows from operating activities(5)   (4,650)   1,535   n.m.   (2,363)   (2,435)   +3%  
N

O

N



G

A

A

P

 

 

 

Adjusted operating income/(loss)(2)   (842)   8,648   (110)%   (1,382)   185   n.m.  
Adjusted operating income margin(3)   (0.5)%   5.5%           (600) bps   (1.7)%   0.3%           (200) bps  
Adjusted diluted EPS(5)   (0.42)   2.48   (117)%   (0.60)   0.08   n.m.  
Industrial free cash flows(4)   (4,525)   (6,045)   +25%   (1,520)   (5,653)   +73%  
 

 

Consolidated shipments(1)   5,484   5,415   +1%   2,820   2,543   +11%  
Combined shipments(1)   5,573   5,526   +1%   2,883   2,595   +11%  

________________________________________________________________________________________________________________________________________

All reported data is unaudited. Reference should be made to the section “Safe Harbor Statement” included elsewhere within this document
n.m – not meaningful

AMSTERDAM – February 26, 2026 — Stellantis N.V. reported its Full Year 2025 results, with Net revenues of €153.5 billion, down 2% from 2024 due to strong FX headwinds and H1 2025 net pricing declines, which were partially offset by higher volume and mix. The Company posted a Net loss of €22.3 billion, driven by €25.4 billion in charges primarily related to a profound strategic shift to meet customer preferences, and reflect shifts in regulatory frameworks.

In 2026, Stellantis’ expanding product wave is broadening market coverage and targeting new opportunities for profitable growth. For example, in North America, the Jeep® Cherokee and Dodge Charger SIXPACK mark a decisive re‑entry into the mid‑SUV and ICE muscle‑car segments, with additional momentum expected from the late‑2025 launch of the Ram 1500 HEMI® V8 and Express models. In South America, the mid-size pickup Ram Dakota anchors the lineup, while in Enlarged Europe, the Citroën C5 Aircross BEV, the Jeep® Compass BEV and the recently launched Fiat 500 Hybrid further strengthen the Company’s ability to meet the full range of its customers’ needs.

Company Delivers Return to Top-Line Growth in H2 2025

Stellantis delivered a solid performance in the second half of 2025, with consolidated shipments reaching 2.8 million units—an increase of 277,000 vehicles, or +11% year-over-year. Growth was broad-based, with every region reporting higher volumes.

  • North America posted the strongest contribution, adding 231,000 units—a +39% year-over-year increase, reflecting the benefits of normalized inventory dynamics, compared with the prior year’s inventory reduction initiative, along with increased commercial momentum in the region.
  • Stellantis’ Net revenues in H2 2025 rose 10% compared with the same period in 2024.

These results reflect the initial impact of improved operational efficiencies, disciplined commercial strategies, and the strength of Stellantis’ global brand portfolio. Furthermore, the renewed focus on quality management is delivering early results, with the number of issues reported for vehicles in their first month of service decreasing by over 50% in North America, and by over 30% in Enlarged Europe since the beginning of 2025.

Executes Decisive Reset to Align with Customers and Support Profitable Growth

On February 6, 2026, Stellantis announced a major reset of its business, resulting in approximately €22.2 billion in charges, excluded from AOI, for the second half of 2025, of which about €6.5 billion are cash payments expected to be made over the next four years. These charges include:

  • Resetting the product plan and EV supply chain to reflect customer demand and shifting regulations;
  • A change in the estimation process for contractual warranty provisions; and
  • Other charges, mainly related to previously announced workforce reductions in Enlarged Europe.

In addition, the reset has empowered regional teams to accelerate decision-making and improve effectiveness across all business areas, while working to build closer, more productive relationships with the Company’s dealer, supplier, institutional and union stakeholders.

2026 Guidance Reiterated Projecting Progressive Improvement in Net Revenue, AOI, and IFCF

The Company expects to see a mid-single-digit percent increase in Net revenues, a low-single-digit AOI margin, and improved Industrial free cash flow generation year over year. Sequential improvement is also expected from the first half to the second half of the year.

Upcoming
Events

  • Full Year 2025 Results Management Call – February 26, 2026, at 2:00 p.m. CET / 8:00 a.m. EST. The webcast and recorded replay will be accessible under the Investors section of the Stellantis corporate website (www.stellantis.com).
  • Annual General Meeting – April 14, 2026.
  • Beginning with Q1 2026 results on April 30, Stellantis will transition to quarterly reporting of earnings and other financial results.
  • Stellantis Investor Day – May 21, 2026, Auburn Hills, Michigan & virtually through webcast. Registration is now open.

About Stellantis

Stellantis N.V. (NYSE: STLA / Euronext Milan: STLAM / Euronext Paris: STLAP) is a leading global automaker, dedicated to giving its customers the freedom to choose the way they move, embracing the latest technologies and creating value for all its stakeholders. Its unique portfolio of iconic and innovative brands includes Abarth, Alfa Romeo, Chrysler, Citroën, Dodge, DS Automobiles, FIAT, Jeep®, Lancia, Maserati, Opel, Peugeot, Ram, Vauxhall, Free2move and Leasys. For more information, visit https://www.stellantis.com.

FULL YEAR 2025 SEGMENT PERFORMANCE

NORTH AMERICA     ENLARGED EUROPE    
€ million, except as otherwise stated 2025   2024   Change   € million, except as otherwise stated 2025   2024   Change
Shipments (000s) 1,472   1,432           +40             Shipments (000s) 2,490   2,576           (86)  
Net revenues 60,962   63,450           (2,488)     Net revenues 57,773   59,010           (1,237)  
AOI (1,892)   2,660           (4,552)     AOI (651)   2,419           (3,070)  
AOI margin (3.1)%   4.2%           (730) bps   AOI margin (1.1)%   4.1%           (520) bps
  • Shipments up 3%, mainly due to increase in Ram LD trucks, Jeep® Wrangler and Gladiator and Chrysler Pacifica, partially offset by Ram Promaster and Jeep® PHEVs
  • Net revenues down 4%, driven largely by foreign exchange impacts from U.S. Dollar and higher incentives levels, partially offset by increased volume, specifically in U.S. retail
  • Adjusted operating income/(loss) down €5 billion, mainly driven by unfavorable mix, U.S. tariffs, change in estimate for contractual warranties and increased incentive spend, partially offset by purchasing and manufacturing performance and improved retail volumes
 
  • Shipments down 3%, mainly due to lower shipments of legacy models of Peugeot, Opel and FIAT brands, partially offset by higher volumes of Opel/Vauxhall Frontera and Fiat Grande Panda
  • Net revenues down 2%, due to pricing pressures and reduced volumes, partially offset by positive powertrain and trim mix
  • Adjusted operating income/(loss) down €3 billion, driven by unfavorable pricing and mix, lower volumes, and higher industrial costs related to warranty and LCV compliance provisions, partially mitigated by improved purchasing and manufacturing performance

MIDDLE EAST & AFRICA     SOUTH AMERICA  
€ million, except as otherwise stated 2025   2024   Change   € million, except as otherwise stated 2025   2024   Change
Combined shipments(1) (000s) 542   534           +8             Shipments (000s) 1,000   912           +88          
Consolidated shipments(1) (000s) 453   423           +30             Net revenues 16,197   15,863           +334          
Net revenues 9,709   10,097           (388)     AOI 1,963   2,272           (309)  
AOI 1,429   1,901           (472)     AOI margin

 

12.1%

 

  14.3%

 

          (220)

 

bps

 

AOI margin 14.7%   18.8%           (410) bps      
  • Consolidated shipments up 7%, mainly driven by increased volumes in Türkiye, partially offset by decreases in Algeria
  • Net revenues down 4%, primarily due to negative foreign exchange translation effects, mainly from Turkish Lira, partially offset by strong increases in net pricing
  • Adjusted operating income/(loss) down €472 million, primarily due to negative foreign exchange transaction and translation effects primarily related to Turkish Lira, partially offset by increased pricing actions
 
  • Shipments up 10%, driven primarily by increased volumes in Argentina, Brazil and Chile
  • Net revenues up 2%, driven by increased volume, mainly in Argentina, largely offset by foreign exchange impacts from Brazilian Real and Argentine Peso
  • Adjusted operating income/(loss) down €309 million, driven by Brazilian Real devaluation impact on industrial costs and Argentine Peso devaluation impact on price in Argentina, partially offset by better volume/mix and a benefit from recognition of Brazilian indirect tax credits

CHINA AND INDIA & ASIA PACIFIC     MASERATI  
€ million, except as otherwise stated 2025   2024   Change   € million, except as otherwise stated 2025   2024   Change
Combined shipments(1) (000s) 61   61           —             Shipments (000s) 7.9   11.3           (3.4)  
Consolidated shipments(1) (000s) 61   61           —             Net revenues 726   1,040           (314)  
Net revenues 1,868   1,993           (125)     AOI (198)   (260)           +62          
AOI 74   (58)           +132             AOI margin

 

(27.3)%

 

  (25.0)%

 

          (230)

 

bps

 

AOI margin 4.0%   (2.9)%           +690         bps      
  • Improved results due to better mix mainly driven by higher Ram sales and fixed costs containment, partially offset by unfavorable foreign exchange translation impacts
 
  • Lower R&D and reduced D&A costs from previously impaired assets, partially offset by decreased net pricing in NA and lower volumes from reduced product portfolio, U.S. tariffs and reduced appetite for luxury products in China

H2 2025 PERFORMANCE

(€ million)   H2 2025   H2 2024   Change
I

F

R

S

 

 

 

Net revenues   79,247   71,861   +10%
Net profit/(loss)   (20,076)   (127)   n.m.
Diluted EPS   (6.96)   (0.05)   n.m.
Cash flows from operating activities(5)   (2,363)   (2,435)   3%
N

O

N



G

A

A

P

 

 

 

Adjusted operating income/(loss)(2)   (1,382)   185   n.m.
Adjusted operating income margin(3)   (1.7)%   0.3%           (200) bps
Adjusted diluted EPS(6)   (0.60)   0.08   n.m.
Industrial free cash flows(4)   (1,520)   (5,653)   73%

NORTH AMERICA     ENLARGED EUROPE  
€ million, except as otherwise stated H2 2025   H2 2024   Change   € million, except as otherwise stated H2 2025   H2 2024   Change
Shipments (000s) 825   594           +231             Shipments (000s) 1,201   1,189           +12          
Net revenues 32,764   25,097           +7,667             Net revenues 28,532   29,041           (509)  
AOI (941)   (1,706)           +765             AOI (660)   359           (1,019)  
AOI margin (2.9)%   (6.8)%           +390         bps   AOI margin (2.3)%   1.2%           (350) bps

MIDDLE EAST & AFRICA       SOUTH AMERICA  
€ million, except as otherwise stated H2 2025   H2 2024   Change   € million, except as otherwise stated H2 2025   H2 2024   Change
Combined shipments(1) (000s) 291   261           +30             Shipments (000s)

 

529

 

  518

 

          +11        

 

 
Consolidated shipments(1) (000s) 228   209           +19                  
Net revenues 4,765   5,092           (327)     Net revenues 8,428   8,496           (68)  
AOI 661   854           (193)     AOI 775   1,122           (347)  
AOI margin 13.9%   16.8%           (290) bps   AOI margin 9.2%   13.2%           (400) bps

CHINA AND INDIA & PACIFIC     MASERATI  
€ million, except as otherwise stated H2 2025   H2 2024   Change   € million, except as otherwise stated H2 2025   H2 2024   Change
Combined shipments(1) (000s) 33   29           +4             Shipments (000s) 3.7   4.8           (1.1)  
Consolidated shipments(1) (000s) 33   29           +4             Net revenues 357   409           (52)  
Net revenues 945   921           +24             AOI (59)   (178)           +119          
AOI 55   (115)           +170             AOI margin

 

(16.5)%

 

  (43.5)%

 

  n.m.

 

 

 

AOI margin 5.8%   (12.5)%   n.m.        

Reconciliations – Full Year

Net revenues from external customers to Net revenues and Net profit to Adjusted operating income

2025 (€ million)   NORTH AMERICA   ENLARGED EUROPE   MIDDLE EAST & AFRICA   SOUTH AMERICA   CHINA AND INDIA & ASIA PACIFIC   MASERATI   OTHER

(*)
  STELLANTIS
Net revenues from external customers           60,962                   57,602                   9,708                   16,031                   1,867                   726                   6,612                   153,508        
Net revenues from transactions with other segments           —                   171                   1                   166                   1                   —                   (339)                           
Net revenues           60,962                   57,773                   9,709                   16,197                   1,868                   726                   6,273                   153,508        
Net profit/(loss)                                       (22,332)
Tax expense/(benefit)                                       (4,273)
Net financial expenses/(income)                                       351        
Operating income/(loss)                                       (26,254)
Adjustments:                                
Restructuring and other costs, net of reversals(A)           (17)           861                   2                   17                                      4                   46                   913        
Takata airbags recall campaign(B)                              590                   27                   5                                                                            622        
Platform impairments(C)           5,700                   270                                                                            613                                      6,583        
Costs related to product plan realignments and program cancellations(D)           6,528                   2,211                   8                   321                   1                   3                                      9,072        
Other Impairments(E)                              79                                                                                               164                   243        
Battery JVs(F)           1,571                   483                                       2,054        
Hydrogen fuel cell program discontinuation(G)                              1,094                                                                                                                  1,094        
CAFE penalty rate(H)           269                                                                                                                                     269        
Stellantis Türkiye disposal(I)                                                 246                                                                                               246        
Change in estimate for contractual warranties(J)           3,252                   878                                                                                                                  4,130        
Other(K)           161                   25                   1                   (35)           (9)                              43                   186        
Total adjustments           17,464                   6,491                   284                   308                   (8)           620                   253                   25,412        
Adjusted operating income

(1)
          (1,892)           (651)           1,429                   1,963                   74                   (198)           (1,567)           (842)

________________________________________________________________________________________________________________________________________________________________________________________
(*) Other activities, unallocated items and eliminations
(A) Primarily related to workforce reductions, mainly in Enlarged Europe
(B) Related to stop-drive campaign on certain vehicles in Enlarged Europe announced in June 2025
(C) Primarily as a result of reduced volumes and profitability expectations, platforms were impaired in North America for €5,700 million, Maserati for €613 million and in Enlarged Europe for €270 million
(D) Primarily related to costs incurred as result of product plan realignments and program cancellations
(E) Impairments in Other activities is related to the Free2Move business, the other impairments in Enlarged Europe relate to write downs of assets on classification to held for sale as well as the impairment of a prepayment to a supplier, which is not expected to be recoverable
(F) Related to steps of rationalizing battery manufacturing capacity
(G) During the year ended December 31, 2025, Stellantis decided to discontinue its hydrogen fuel cell strategy. As a result, the following items have been impaired: (i) investment in Symbio (€324 million), (ii) loans granted to Symbio (€146 million), (iii) capitalized development expenditures and property, plant and equipment related to fuel cells (€341 million), (iv) in addition, provisions for risks were recognized (€210 million) and (v) other expenses (€73 million)
(H) As a result of the elimination of CAFE fines with the enactment of OBBB, the Company recognized a net expense of €97 million, comprised of net €172 million of CAFE credits recognized as a reduction of Cost of revenues, which remains included in Adjusted operating income as these amounts reduced prior year CAFE fines, and a net expense of €269 million, which is excluded from AOI and comprised of (i) elimination of the CAFE provision of €844 million, (ii) impairment of the regulatory credit assets of €609 million, and (iii) onerous contracts related to contractual purchase commitments for CAFE credits of €504 million
(I) Sale of Stellantis Türkiye to the Company’s joint venture, Tofas, for which the Company recognized an estimated loss on disposal of €246 million, driven primarily by the recycling of the cumulative translation reserve from Equity to the Consolidated Income Statement upon disposal
(J) Related to the change in estimate for contractual warranty provisions, resulting from the reassessment of the estimation process, taking into account recent increases in cost inflation and a deterioration in quality, as a result of operational choices, which did not deliver the expected quality performance
(K) Comprised primarily of (i) adjustments to costs previously recognized to support the workforce during the transformation of certain plants in North America, (ii) gains/(losses) recognized on the disposal of non-significant entities and on dilution of certain of our equity method investees, including Archer.

2024 (€ million)   NORTH AMERICA   ENLARGED EUROPE   MIDDLE EAST & AFRICA   SOUTH AMERICA   CHINA AND INDIA & ASIA PACIFIC   MASERATI   OTHER

(*)
  STELLANTIS
Net revenues from external customers           63,449                   58,844                   10,109                   15,883                   1,991                   1,038                   5,564                   156,878        
Net revenues from transactions with other segments           1                   166                   (12)                   (20)                   2                   2                   (139)                           
Net revenues           63,450                   59,010                   10,097                   15,863                   1,993                   1,040                   5,425                   156,878        
Net profit/(loss)                                       5,520        
Tax expense/(benefit)                                       (1,488)
Net financial expenses/(income)                                       (345)
Operating income/(loss)                                       3,687        
Adjustments:                                
Restructuring and other costs, net of reversals

(A)
          510                   1,027                   1                   20                   6                   22                   31                   1,617        
Impairment expense and supplier obligations, net of reversals

(B)
          31                   207                   2                                      16                   1,526                   25                   1,807        
Takata airbags recall campaign, net of recoveries

(C)
                             711                   21                   36                                                                            768        
Lifetime onerous contracts

(D)
          636                                                                            1                                                         637        
Other

(E)
          62                   (6)                              32                   (5)                              49                   132        
Total adjustments           1,239                   1,939                   24                   88                   18                   1,548                   105                   4,961        
Adjusted operating income

(1)
          2,660                   2,419                   1,901                   2,272                   (58)           (260)           (286)           8,648        

________________________________________________________________________________________________________________________________________________________________________________________
(*) Other activities, unallocated items and eliminations
(A) Primarily related to workforce reductions, mainly in Enlarged Europe and North America
(B) Primarily related to (i) €1,063 million of impairments of certain platform assets in Maserati and Enlarged Europe, net of reversal, driven by projected decreases in margins for certain models and the cancellation of certain projects prior to launch, (ii) €230 million of provisions accrued for supplier obligations, relating to projects in development which were cancelled prior to launch (and for which the related capitalized R&D was impaired under (i) above), and (iii) €514 million of goodwill impairments related to the Maserati segment
(C) Extension of Takata airbags recall campaign
(D) Provision primarily related to lifetime service contracts sold in North America prior to the merger determined to be onerous during 2024
(E) Consisting of other adjustments which are individually insignificant

Diluted EPS to Adjusted diluted EPS(6)

Results from continuing operations        
(€ million, except as otherwise stated)   2025   2024
Net profit attributable to owners of the parent           (22,368)           5,473        
Weighted average number of shares outstanding (000)           2,886,684                   2,949,652        
Number of shares deployable for share-based compensation (000)                              26,168        
Weighted average number of shares outstanding for diluted earnings per share (000)           2,886,684                   2,975,820        
Diluted earnings per share (A) (€/share)           (7.75)           1.84        
         
Adjustments, per above           25,412                   4,961        
Tax impact on adjustments(B)           (5,185)           (799)
Unusual items related to income taxes(B)           932                   (2,266)
Total adjustments, net of taxes           21,159                   1,896        
Impact of adjustments above, net of taxes, on Diluted earnings per share from continuing operations (B) (€/share)           7.33                   0.64        
Adjusted Diluted earnings per share

(6)

(€/share) (A+B)
          (0.42)           2.48        

______________________________________________________________________________________________________________________________________________
(A) Tax impact on adjustments is calculated based on the expected local country tax implications for each adjustment
(B) Unusual items related to income taxes relate to the derecognition of deferred tax assets in Germany in 2025, and the recognition of deferred tax assets in Brazil in 2024

Cash flows from operating activities to Industrial free cash flows

(€ million)   2025   2024
Cash flows from/(used in) operating activities

(5)
          (4,650)           1,535        
Less: Financial services, net of inter-segment eliminations           (9,700)           (5,209)
Less: Capital Expenditures and capitalized research and development expenditures and change in amounts payable on property, plant and equipment and intangible assets for industrial activities           9,090                   10,761        
Add: Proceeds from disposal of assets and other changes in investing activities           591                   303        
Less: Contributions of equity to joint ventures and minor acquisitions of consolidated subsidiaries and equity method and other investments           1,116                   2,376        
Add: Defined benefit pension contributions, net of tax           40                   45        
Industrial free cash flows

(4)
          (4,525)           (6,045)

Debt to Industrial net financial position

(€ million)   December 31, 2025   December 31, 2024
Debt           (45,947)           (37,227)
Current financial receivables from jointly-controlled financial services companies           603                   674        
Derivative financial assets/(liabilities), net and collateral deposits           181                   222        
Financial securities           1,362                   4,468        
Cash and cash equivalents           30,146                   34,100        
Industrial net financial position classified as held for sale                              169        
Net financial position           (13,655)           2,406        
Less: Net financial position of financial services           (20,349)           (12,722)
Industrial net financial position

(7)
          6,694                   15,128        

Available liquidity

(€ million)    

December 31, 2025

  December 31, 2024
Cash, cash equivalents and financial securities(8)           31,508                   38,568        
Undrawn committed credit lines           18,287                   12,915        
Cash, cash equivalents and financial securities – included within Assets held for sale                              297        
Total Available liquidity

(9)
          49,795                   51,780        
of which: Available liquidity of the Industrial Activities           45,711                   49,481        

Reconciliations – H2

Net revenues from external customers to Net revenues and Net profit to Adjusted operating income

H2 2025 (€ million)   NORTH AMERICA   ENLARGED EUROPE   MIDDLE EAST & AFRICA   SOUTH AMERICA   CHINA AND INDIA & ASIA PACIFIC   MASERATI   OTHER

(*)
  STELLANTIS
Net revenues from external customers           32,764                   28,439                   4,770                   8,335                   948                   358                   3,633                   79,247        
Net revenues from transactions with other segments           —                   93                   (5)                   93                   (3)                   (1)                   (177)                           
Net revenues           32,764                   28,532                   4,765                   8,428                   945                   357                   3,456                   79,247        
Net profit/(loss)                                       (20,076)
Tax expense/(benefit)                                       (3,659)
Net financial expenses/(income)                                       191        
Operating income/(loss)                                       (23,544)
Adjustments:                                
Restructuring and other costs, net of reversals(A)           24                   330                   2                   13                                      4                   18                   391        
Takata airbags recall campaign(B)                              351                   27                   5                                                                            383        
Platform impairments(C)           5,700                   244                                                                            61                                      6,005        
Costs related to product plan realignments and program cancellations(D)           6,201                   2,077                                      2                                      3                                      8,283        
Other Impairments(E)                              79                                                                                               164                   243        
Battery JVs(F)           1,571                   483                                                                                                                  2,054        
Fuel cell program discontinuation(G)                              361                                                                                                                  361        
CAFE penalty rate                                                                                                                                                        
Stellantis Türkiye disposal                                                                                                                                                        
Change in estimate for contractual warranties(H)           3,252                   878                                                                                                                  4,130        
Other(I)           244                   51                   1                   (35)           (11)           (3)           65                   312        
Total adjustments           16,992                   4,854                   30                   (15)           (11)           65                   247                   22,162        
Adjusted operating income

(1)
          (941)           (660)           661                   775                   55                   (59)           (1,213)           (1,382)

________________________________________________________________________________________________________________________________________________________________________________________
(*) Other activities, unallocated items and eliminations
(A) Primarily related to workforce reductions, mainly in Enlarged Europe
(B) Related to stop-drive campaign on certain vehicles in Enlarged Europe announced in June 2025
(C) Primarily as a result of reduced volumes and profitability expectations, platforms were impaired in North America for €5,700 million, Maserati for €61 million and in Enlarged Europe for €244 million
(D) Primarily related costs incurred as result of product plan realignments and program cancellations
(E) Impairments in Other activities is related to the Free2Move business, the other impairments in Enlarged Europe relate to write downs of assets on classification to held for sale as well as the impairment of a prepayment to a supplier, which is not expected to be recoverable
(F) Related to steps of rationalizing battery manufacturing capacity
(G) During the year ended December 31, 2025, Stellantis decided to discontinue its hydrogen fuel cell strategy. As a result, the following items have been impaired: (i) investment in Symbio (€145 million), (ii) reversal of funding commitments (€16 million), (iii) capitalized development expenditures and property, plant and equipment related to fuel cells (€12 million), (iv) in addition, provisions for risks were recognized (€147 million) and (v) other expenses (€73 million)
(H) Related to the change in estimate for contractual warranty provisions, resulting from the reassessment of the estimation process, taking into account recent increases in cost inflation and a deterioration in quality, as a result of operational choices, which did not deliver the expected quality performance
(I) Comprised primarily of (i) adjustments to costs previously recognized to support the workforce during the transformation of certain plants in North America, (ii) gains/(losses) recognized on the disposal of non-significant entities and on dilution of certain of our equity method investees.

H2 2024 (€ million)   NORTH AMERICA   ENLARGED EUROPE   MIDDLE EAST & AFRICA   SOUTH AMERICA   CHINA AND INDIA & ASIA PACIFIC   MASERATI   OTHER

(*)
  STELLANTIS
Net revenues from external customers           25,098                   28,996                   5,104                   8,510                   920                   407                   2,826                   71,861        
Net revenues from transactions with other segments           (1)                   45                   (12)                   (14)                   1                   2                   (21)                           
Net revenues           25,097                   29,041                   5,092                   8,496                   921                   409                   2,805                   71,861        
Net profit/(loss)                                       (127)
Tax expense/(benefit)                                       (2,830)
Net financial expenses/(income)                                       5        
Operating income/(loss)                                       (2,952)
Adjustments:                                
Restructuring and other costs, net of reversals

(A)
          462                   (60)           1                   11                   6                   (3)           (12)           405        
Impairment expense and supplier obligations

(B)
          29                   164                   2                                      5                   1,202                   17                   1,419        
Takata recall campaign

(C)
                             637                   17                   35                                                                            689        
Lifetime onerous contract

(D)
          636                                                                            1                                                         637        
Other

(E)
          (57)           (8)                              3                   (6)                              55                   (13)
Total adjustments           1,070                   733                   20                   49                   6                   1,199                   60                   3,137        
Adjusted operating income

(1)
          (1,706)           359                   854                   1,122                   (115)           (178)           (151)           185        

________________________________________________________________________________________________________________________________________________________________________________________
(*) Other activities, unallocated items and eliminations
(A) Primarily related to workforce reductions, mainly in North America
(B) Primarily related to (i) €730 million of impairments of certain platform assets in Maserati and Enlarged Europe, net of reversal, driven by projected decreases in margins for certain models and the cancellation of certain projects prior to launch, (ii) €175 million of provisions accrued for supplier obligations, relating to projects in development which were cancelled prior to launch (and for which the related capitalized R&D was impaired under (i) above), and (iii) €514 million of goodwill impairments related to the Maserati segment
(C) Extension of Takata airbags recall campaign
(D) Provision primarily related to lifetime service contracts sold in North America prior to the merger determined to be onerous during 2024
(E) Consisting of other adjustments which are individually insignificant

Diluted EPS to Adjusted diluted EPS(6)

Results from continuing operations        
(€ million, except as otherwise stated)   H2 2025   H2 2024
Net profit/(loss) attributable to owners of the parent           (20,128)           (151)
Weighted average number of shares outstanding (000)           2,890,691                   2,897,090        
Number of shares deployable for share-based compensation (000)                              23,914        
Weighted average number of shares outstanding for diluted earnings per share (000)           2,890,691                   2,921,004        
Diluted earnings/(loss) per share (A) (€/share)           (6.96)           (0.05)
         
Adjustments, per above           22,162                   3,137        
Tax impact on adjustments(A)           (4,715)           (483)
Unusual items related to income taxes(B)           932                   (2,266)
Total adjustments, net of taxes           18,379                   388        
Impact of adjustments above, net of taxes, on Diluted earnings per share from continuing operations (B) (€/share)           6.36                   0.13        
Adjusted Diluted earnings per share

(6)

(€/share) (A+B)
          (0.60)           0.08        

_____________________________________________________________________________________________________________________________________________
(A) Tax impact on adjustments is calculated based on the expected local country tax implications for each adjustment
(B) Unusual items related to income taxes relate to the derecognition of deferred tax assets in Germany in 2025, and the recognition of deferred tax assets in Brazil in 2024
Cash flows from operating activities to Industrial free cash flows

(€ million)   H2 2025   H2 2024
Cash flows from/(used in) operating activities

(5)
          (2,363)                   (2,435)
Less: Financial services, net of inter-segment eliminations           (5,303)                   (2,825)
Less: Capital Expenditures and capitalized research and development expenditures and change in amounts payable on property, plant and equipment and intangible assets for industrial activities           3,954                   5,323        
Add: Proceeds from disposal of assets and other changes in investing activities           118                   140        
Less: Contributions of equity to joint ventures and minor acquisitions of consolidated subsidiaries and equity method and other investments           636                   881        
Add: Defined benefit pension contributions, net of tax           12                   21        
Industrial free cash flows

(4)
          (1,520)                   (5,653)


NOTES

(1) Combined shipments include shipments by the Company’s consolidated subsidiaries and unconsolidated joint ventures, whereas Consolidated shipments only include shipments by the Company’s consolidated subsidiaries. This includes the vehicles produced by our joint ventures and associates (including Leapmotor) which are distributed by our consolidated subsidiaries. In addition to the volumes included in consolidated shipments, combined shipments also includes the vehicles distributed by our joint ventures (such as Tofas). Figures by segments may not add up due to rounding.
(2) Adjusted operating income/(loss) excludes from Net profit/(loss) from continuing operations adjustments comprising restructuring and other termination costs, impairments, asset write-offs, disposals of investments and unusual operating income/(expense) that are considered rare or discrete events and are infrequent in nature, as inclusion of such items is not considered to be indicative of the Company’s ongoing operating performance, and also excludes Net financial expenses/(income) and Tax expense/(benefit).
Unusual operating income/(expense) are impacts from strategic decisions, as well as events considered rare or discrete and infrequent in nature, as inclusion of such items is not considered to be indicative of the Company’s ongoing operating performance. Unusual operating income/(expense) includes, but may not be limited to: impacts from strategic decisions to rationalize Stellantis’ core operations; facility-related costs stemming from Stellantis’ plans to match production capacity and cost structure to market demand, and convergence and integration costs directly related to significant acquisitions or mergers.
(3) Adjusted operating income/(loss) margin is calculated as Adjusted operating income/(loss) divided by Net revenues.
(4) Industrial free cash flows is our key cash flow metric and is calculated as Cash flows from operating activities less: (i) cash flows from operating activities from discontinued operations; (ii) cash flows from operating activities related to financial services, net of eliminations; (iii) investments in property, plant and equipment and intangible assets for industrial activities; (iv) contributions of equity to joint ventures and minor acquisitions of consolidated subsidiaries and equity method and other investments; and adjusted for: (i) net intercompany payments between continuing operations and discontinued operations; (ii) proceeds from disposal of assets and (iii) contributions to defined benefit pension plans, net of tax. The timing of Industrial free cash flows may be affected by the timing of monetization of receivables, factoring and the payment of accounts payables, as well as changes in other components of working capital, which can vary from period to period due to, among other things, cash management initiatives and other factors, some of which may be outside of the Company’s control. In addition, Industrial free cash flows is one of the metrics used in the determination of the annual performance bonus for eligible employees, including members of the senior management.
(5) Effective H1 2025, two types of cash flows were reclassified to cash flows from operating activities: (i) the net change in receivables related to financial services activities have been reclassified from investing activities as these are part of our principal revenue-generating activities and (ii) certain financial receivables related to factoring transactions from financing activities. Comparative figures for FY 2024 and H2 2024 have been reclassified accordingly.

(€ million)   FY 2024 as reported   Adjustment: Financial services activities   Adjustment: Financial receivables   FY 2024 as adjusted
Cash flows from operating activities           4,008                   (3,455)           982                   1,535        
Less: Financial services, net of inter-segment eliminations           (2,736)           3,455                   (982)           (5,209)
Less: Capital Expenditures and capitalized research and development expenditures and change in amounts payable on property, plant and equipment and intangible assets for industrial activities           10,761                                                         10,761        
Add: Proceeds from disposal of assets and other changes in investing activities           303                                                         303        
Less: Contributions of equity to joint ventures and minor acquisitions of consolidated subsidiaries and equity method and other investments           2,376                                                         2,376        
Add: Defined benefit pension contributions, net of tax           45                                                         45        
Industrial free cash flows           (6,045)                                                 (6,045)

(€ million)   H2 2024 as reported   Adjustment: Financial services activities   Adjustment: Financial receivables   H2 2024 as adjusted
Cash flows from operating activities           (881)           (1,716)           162                   (2,435)
Less: Financial services, net of inter-segment eliminations           (1,271)           1,716                   (162)           (2,825)
Less: Capital Expenditures and capitalized research and development expenditures and change in amounts payable on property, plant and equipment and intangible assets for industrial activities           5,323                                                         5,323        
Add: Proceeds from disposal of assets and other changes in investing activities           140                                                         140        
Less: Contributions of equity to joint ventures and minor acquisitions of consolidated subsidiaries and equity method and other investments           881                                                         881        
Add: Defined benefit pension contributions, net of tax           21                                                         21        
Industrial free cash flows           (5,653)                                                 (5,653)

(6) Adjusted diluted earnings per share (“EPS”) is calculated by adjusting Diluted earnings per share for the post-tax impact per share of the same items excluded from Adjusted operating income as well as tax expense/(benefit) items that are considered rare or infrequent, or whose nature would distort the presentation of the ongoing tax charge of the Company. We believe this non-GAAP measure is useful because it also excludes items that we do not believe are indicative of the Company’s ongoing operating performance and provides investors with a more meaningful comparison of the Company’s ongoing quality of earnings. Adjusted diluted EPS should not be considered as a substitute for Basic earnings per share, Diluted earnings per share from operations or other methods of analyzing our quality of earnings as reported under IFRS.
(7) Industrial net financial position is calculated as Debt plus derivative financial liabilities related to industrial activities less (i) cash and cash equivalents, (ii) financial securities that are considered liquid, (iii) current financial receivables from the Company or its jointly controlled financial services entities and (iv) derivative financial assets and collateral deposits. Therefore, debt, cash and cash equivalents and other financial assets/ liabilities pertaining to Stellantis’ financial services entities are excluded from the computation of the Industrial net financial position. Industrial net financial position includes the Industrial net financial position classified as held for sale.
8) Financial securities are comprised of short term or marketable securities which represent temporary investments but do not satisfy all the requirements to be classified as cash equivalents as they may be subject to risk of change in value (even if they are short-term in nature or marketable).
(9) The majority of our liquidity is available to our treasury operations in Europe and U.S.; however, liquidity is also available to certain subsidiaries which operate in other countries. Cash held in such countries may be subject to restrictions on transfer depending on the foreign jurisdictions in which these subsidiaries operate. Based on our review of such transfer restrictions in the countries in which we operate and maintain material cash balances, (and in particular in Argentina, in which we have €354 million cash and securities at December 31, 2025 (€680 million at December 31, 2024), and in Algeria, in which we have €276 million cash at December 31, 2025 (€276 million at December 31, 2024)), we do not believe such transfer restrictions had an adverse impact on the Company’s ability to meet its liquidity requirements at the dates presented above. Cash and cash equivalents also include €663 million at December 31, 2025 (€451 million at December 31, 2024) held in bank deposits which are restricted to the operations related to securitization programs and warehouses credit facilities of SFS U.S.

Rankings, market share and other industry information are derived from third-party industry sources (e.g. Agence Nationale des Titres Sécurisés (ANTS), Associação Nacional dos Fabricantes de Veículos Automotores (ANFAVEA), Ministry of Infrastructure and Sustainable Mobility (MIMS), S&P Global, Ward’s Automotive) and internal information unless otherwise stated.

For purposes of this document, and unless otherwise stated industry and market share information are for passenger cars (PC) plus light commercial vehicles (LCV), except as noted below:

  • Enlarged Europe excludes Russia and Belarus. From 2025, this includes Israel and Palestine (prior periods have not been restated);
  • Middle East & Africa excludes Iran, Sudan and Syria. From 2025, this excludes Israel and Palestine (prior periods have not been restated);
  • South America excludes Cuba;
  • India & Asia Pacific reflects aggregate for major markets where Stellantis competes (Japan (PC), India (PC), South Korea (PC + Pickups), Australia, New Zealand and South East Asia);
  • China represents PC only and includes licensed sales from DPCA; and
  • Maserati reflects aggregate for 17 major markets where Maserati competes and is derived from S&P Global data, Maserati competitive segment and internal information.

Prior period figures have been updated to reflect current information provided by third-party industry sources.

EU30 = EU 27 (excluding Malta), Iceland, Norway, Switzerland and UK.

Low emission vehicles (LEV) = battery electric (BEV), plug-in hybrid (PHEV), range-extender electric vehicle (REEV) and fuel cell electric (FCEV) vehicles.

All Stellantis reported BEV and LEV sales include Citroën Ami, Opel Rocks-e and Fiat Topolino; in countries where these vehicles are classified as quadricycles, they are excluded from Stellantis reported combined sales, industry sales and market share figures.

SAFE HARBOR STATEMENT

This document, in particular references to “FY 2026 Financial Guidance”, contains forward looking statements. In particular, statements regarding future financial performance and the Company’s expectations as to the achievement of certain targeted metrics, including revenues, industrial free cash flows, vehicle shipments, capital investments, research and development costs and other expenses at any future date or for any future period are forward-looking statements. These statements may include terms such as “may”, “will”, “expect”, “could”, “should”, “intend”, “estimate”, “anticipate”, “believe”, “remain”, “on track”, “design”, “target”, “objective”, “goal”, “forecast”, “projection”, “outlook”, “prospects”, “plan”, or similar terms. Forward-looking statements are not guarantees of future performance. Rather, they are based on the Company’s current state of knowledge, future expectations and projections about future events and are by their nature, subject to inherent risks and uncertainties. They relate to events and depend on circumstances that may or may not occur or exist in the future and, as such, undue reliance should not be placed on them.

Actual results may differ materially from those expressed in forward-looking statements as a result of a variety of factors, including: the Company’s ability to maintain vehicle shipment volumes; changes in the global financial markets, general economic environment and changes in demand for automotive products, which is subject to cyclicality; changes in trade policy, the imposition of global and regional tariffs targeted to the automotive industry; the Company’s ability to accurately predict the market demand for electrified vehicles; the Company’s ability to offer innovative, attractive products; a significant malfunction, disruption or security breach compromising information technology systems or the electronic control systems contained in the Company’s vehicles; the Company’s ability to attract and retain experienced management and employees; exchange rate fluctuations, interest rate changes, credit risk and other market risks; increases in costs, disruptions of supply or shortages of raw materials, parts, components and systems used in the Company’s vehicles; changes in local economic and political conditions; the enactment of tax reforms or other changes in tax laws and regulations; the level of governmental economic incentives available to support the adoption of battery electric vehicles; the impact of increasingly stringent regulations regarding fuel efficiency and greenhouse gas and tailpipe emissions; various types of claims, lawsuits, governmental investigations and other contingencies, including product liability and warranty claims and environmental claims, investigations and lawsuits; material operating expenditures in relation to compliance with environmental, health and safety regulations; the level of competition in the automotive industry, which may increase due to consolidation and new entrants; exposure to shortfalls in the funding of the Company’s defined benefit pension plans; the Company’s ability to provide or arrange for access to adequate financing for dealers and retail customers; risks related to the operations of financial services companies; the Company’s ability to access funding to execute its business plan; the Company’s ability to realize anticipated benefits from joint venture arrangements; disruptions arising from political, social and economic instability; risks associated with the Company’s relationships with employees, dealers and suppliers; the Company’s ability to maintain effective internal controls over financial reporting; developments in labor and industrial relations and developments in applicable labor laws; earthquakes or other disasters; and other risks and uncertainties.

Any forward-looking statements contained in this document speak only as of the date of this document and the Company disclaims any obligation to update or revise publicly forward looking statements. Further information concerning the Company and its businesses, including factors that could materially affect the Company’s financial results, is included in the Company’s reports and filings with the U.S. Securities and Exchange Commission and AFM.

Attachment



HAFNIA LIMITED: Key Information Relating to Dividend for the Fourth Quarter 2025

HAFNIA LIMITED: Key Information Relating to Dividend for the Fourth Quarter 2025

SINGAPORE–(BUSINESS WIRE)–
Reference is made to the announcement made by Hafnia Limited (“Hafnia” or the “Company”, OSE ticker code: “HAFNI”, NYSE ticker code: “HAFN”) on 26 February 2026 announcing the Company’s fourth quarter results and cash dividend.

Key information relating to the cash dividend paid by the Company for the fourth quarter 2025:

  • Date of approval: 25 February 2026

  • Record date: 6 March 2026

  • Dividend amount: 0.1762 per share

  • Declared currency: USD. Dividends payable to shares registered in the Euronext VPS will be distributed in NOK, with the conversion from USD to NOK taking place two business days prior to the payment date to shareholders in VPS.

Shares registered in the Euronext VPS Oslo Stock Exchange:

  • Last trading day including right to dividends: 4 March 2026

  • Ex-date: 5 March 2026
  • Payment date: On or about 18 March 2026

Shares registered in the Depository Trust Company:

  • Last trading day including right to dividends: 5 March 2026

  • Ex-date: 6 March 2026
  • Payment date: On or about 13 March 2026

This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

About Hafnia Limited:

Hafnia is one of the world’s leading tanker owners, transporting oil, oil products and chemicals for major national and international oil companies, chemical companies, as well as trading and utility companies.

As owners and operators of around 200 vessels, we offer a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk. Hafnia has offices in Singapore, Copenhagen, Houston, and Dubai and currently employs over 4000 employees onshore and at sea.

Hafnia is part of the BW Group, an international shipping group involved in oil and gas transportation, floating gas infrastructure, environmental technologies, and deep-water production for over 80 years.

For further information, please contact:

Mikael Skov

CEO Hafnia Limited

+65 8533 8900

KEYWORDS: Asia Pacific Europe Norway Singapore Southeast Asia

INDUSTRY KEYWORDS: Chemicals/Plastics Maritime Logistics/Supply Chain Management Oil/Gas Transport Manufacturing Energy

MEDIA:

Logo
Logo

Hafnia Limited Announces Financial Results For The Three and Twelve Months Ended 31 December 2025

Hafnia Limited Announces Financial Results For The Three and Twelve Months Ended 31 December 2025

SINGAPORE–(BUSINESS WIRE)–
Hafnia Limited (“Hafnia”, the “Company” or “we”, OSE ticker code: “HAFNI”, NYSE ticker code: “HAFN”), a leading product tanker company with a diversified and modern fleet of over 120 vessels, today announced results for the three and twelve months ended 31 December 2025.

The full report can be found in the Investor Relations section of Hafnia’s website: https://investor.hafniabw.com/financials/quarterly-results/default.aspx

Highlights and Recent Activity

Fourth Quarter 2025

  • Recorded net profit of USD 109.7 million or USD 0.22 per share1 compared to USD 79.6 million or USD 0.16 per share in Q4 2024.

  • Fee-based businesses generated earnings of USD 6.9 million compared to USD 6.9 million in Q4 2024.

  • Time Charter Equivalent (TCE)3 earnings were USD 259.0 million compared to USD 233.6 million in Q4 2024, resulting in an average TCE3 of USD 27,346 per day.

  • Adjusted EBITDA3 of USD 149.7 million compared to USD 131.2 million in Q4 2024.

  • 76% of total earning days of the fleet were covered for Q1 2026 at USD 29,979 per day as of 11 February 2026.
  • Net asset value (NAV)4 was approximately USD 3.5 billion, or approximately USD 7.04 per share (NOK 70.79), at quarter end.

  • Hafnia will distribute a total of USD 87.7 million, or USD 0.1762 per share, in dividends, corresponding to a payout ratio of 80%.

Full Year 2025

  • Recorded net profit of USD 339.7 million or USD 0. 68 per share1 as compared to USD 774.0 million or USD 1.52 per share in full year 2024.

  • Fee-based businesses generated earnings of USD 29.8 million2 compared to USD 35.2 million in full year 2024.

  • Time Charter Equivalent (TCE)3 earnings were USD 955.9 million compared to USD 1,391.3 million for full year 2024, resulting in an average TCE3 of USD 25,206 per day.

  • Adjusted EBITDA3 of USD 559.5 million compared to USD 992.3 million in full year 2024.

1

Based on weighted average number of shares as at 31 December 2025.

2

Excluding a one-off item amounting to USD 1.3 million in YTD 2025. From mid-May 2025, the Group transferred its bunker procurement business to its joint venture, Seascale Energy, which is equity accounted.

3

See Non-IFRS Measures Section below.

4

NAV is calculated using the fair value of Hafnia’s owned vessels (including joint venture vessels).

Mikael Skov, CEO of Hafnia, commented:

While 2025 began on a softer footing, market conditions strengthened steadily through the second half of the year. The product tanker market remained seasonally firm in the fourth quarter, allowing the year to close on a strong note. This improvement was underpinned by continued growth in clean petroleum product exports, increased crude oil production prompting a meaningful shift of LR2 vessels into dirty trading, and the sustained impact of geopolitical developments, particularly in Russia and the Red Sea, which continue to exert significant influence on the product tanker market.

With this, I am pleased to announce that we delivered our strongest quarterly result of 2025. In Q4, we recorded a net profit of USD 109.7 million, which included USD 9.5 million from gains on vessel sales, while our fee-based business generated USD 6.9 million. This brings our full-year net profit to USD 339.7 million, marking another year of strong performance.

As per earlier quarters of 2025, our Q4 results reflect the impact of several vessels undergoing scheduled drydocking, resulting in approximately 550 off-hire days. This was around 120 days higher than expected, mainly due to unscheduled repairs for three vessels. We expect drydocking activity to continue into the upcoming quarters of 2026, but anticipate off-hire days to taper off slightly, to around 180 in Q1 2026.

At the end of the fourth quarter, our net asset value (NAV1) stood at approximately USD 3.5 billion, equivalent to USD 7.04 (~NOK 70.79) per share. Our net Loan-to-Value (LTV) ratio increased from 20.5% in the third quarter to 24.9%, primarily reflecting our investment in TORM, whose market value is included in the calculation. This was partly offset by higher vessel market valuations and strong operational cash flow generation.

In line with our ongoing fleet renewal strategy, we continue to divest older tonnage. In January 2026, we completed the sale of the 2013-built MR vessels, the Hafnia Libra and the Hafnia Phoenix, and took delivery of the Ecomar Gironde, the fourth and final dual-fuel IMO II MR tanker under our Ecomar joint venture with Socatra of France. Over the first quarter, we have further sold four LR1 vessels, two MR vessels and four Handy vessels to external parties, which are pending delivery to the buyers.

I am pleased to announce a 80% payout ratio for the fourth quarter. We will distribute a total of USD 87.7 million in dividends, or USD 0.1762 per share. This brings our total dividends for 2025 results to USD 0.5457 per share which, based on our share price at the end of 2025, represents a dividend yield of approximately 10%.

On 22 December 2025, Hafnia completed its acquisition of 13.97% of TORM shares from Oaktree. We acquired the shares with a belief that consolidation with TORM represents a compelling long-term value creation opportunity for both companies and their respective shareholders through enhanced scale, meaningful operational synergies, and improved capital markets positioning. While we are convinced of the rationale for consolidation, we cannot predict the timing or outcome, and will remain patient and disciplined in our approach to ensure that any steps we take are aligned with our commitment to create value for Hafnia’s shareholders.

Looking ahead to 2026, we entered the year at seasonally strong rate levels, although we anticipate a gradual easing as newbuild deliveries enter the market. A continued firm crude market is, however, expected to partially mitigate the impact of additional supply. Demand fundamentals remain sound, while political uncertainty continues to represent a key variable, such as potential changes to sanctions regimes, including those affecting Venezuela, Iran, and Russia, which could materially affect trade flows and influence the overall market outlook. Accordingly, shifts in trade policy, evolving oil transportation patterns, and ongoing geopolitical tensions are likely to remain the principal swing factors shaping market conditions for the year ahead.

As of 11 February 2026, 76% of our Q1 earning days are covered at an average of USD 29,979 per day, and 33% of the earning days for 2026 are covered at USD 27,972 per day.

We remain encouraged by the strength of the market and believe that 2026 is set to deliver another year of robust earnings.

1

NAV is calculated using the fair value of Hafnia’s owned vessels (including joint venture vessels).

Fleet1

At the end of the quarter, Hafnia’s fleet consisted of 114 owned vessels2 and 9 chartered-in vessels. The Group’s total fleet includes 10 LR2s, 32 LR1s (including two bareboat-chartered in and two time-chartered in), 57 MRs of which 12 are IMO II (including seven time-chartered in), and 24 Handy vessels of which 18 are IMO II (including one bareboat-chartered in).

The average estimated broker value of the owned fleet1 was USD 3,897 million, of which USD 3,472 million relates to Hafnia’s 100% owned fleet, and USD 425 million relates to Hafnia’s 50% share in the joint venture fleet.

Including Hafnia’s 50% share in the joint venture fleet, the LR2 vessels had a broker value of USD 570 million2, the LR1 fleet had a broker value of USD 980 million3, the MR fleet had a broker value of USD 1,584 million4and the Handy vessels had a broker value of USD 763 million5. The unencumbered vessels had a broker value of USD 730 million. The chartered-in fleet had a right-of-use asset book value of USD 38.4 million with a corresponding lease liability of USD 37.8 million.

1

Vessels under construction that are not delivered as at the financial reporting date are not included in the fleet count.

2

Including bareboat chartered in vessels; six LR1s and four LR2s owned through 50% ownership in the Vista Shipping Joint Venture, two MRs owned through 50% ownership in the H&A Shipping Joint Venture and three IMO II MRs owned through 50% ownership in the Ecomar Joint Venture; and two MRs classified as held for sale.

3

Including USD 297 million relating to Hafnia’s 50% share of six LR1s and four LR2s owned through 50% ownership in the Vista Shipping Joint Venture

4

Including USD 128 million relating to Hafnia’s 50% share of two MRs owned through 50% ownership in the H&A Shipping Joint Venture and three IMO II MRs owned through 50% ownership in the Ecomar Joint Venture; and IMO II MR vessels; and two MRs classified as held for sale.

5

Including IMO II Handy vessels

Market Review & Outlook

Market Fundamentals

The product tanker market began 2025 on a softer footing, but strengthened as the year progressed, supported by rising export volumes, increased crude production, and a notable shift of LR2 vessels shifting into dirty trading. In Europe, draws on diesel inventories further boosted tonne‑mile demand as stocks were replenished with cargoes from the East.

In early 2026, both dirty and clean product volumes on the water have increased. Dirty volumes have been driven largely by sanctioned barrels awaiting buyers, while clean volumes reflect strong export flows from the US Gulf, the Middle East, and China. Global oil demand remains resilient and is expected to grow further in 2026.

Geopolitical Developments

Despite some progress regarding US-China port fees, geopolitical tensions in Iran, Venezuela, and Russia continue to influence trade flows. Any material changes, particularly relating to Venezuelan exports, could provide additional support for Aframax and LR2 demand. We expect sanctions on Russia to remain, thereby limiting the participation of sanctioned tonnage in mainstream trade and therefore continuing to support demand for compliant vessels.

Forward View

The supply backdrop remains broadly supportive. Asset values stabilized through 2025, while deliveries remained elevated and scrapping activity stayed limited. Another year of high newbuild deliveries is expected in 2026, while continued vessel sanctions, an ageing global fleet, and a firm crude market are expected to offset some of the incremental supply.

Despite the significant orderbook, the overall supply outlook is more balanced than headline figures suggest. Scrap potential is increasing as the fleet continues to age, while the dark and sanctioned fleet faces growing regulatory and operational constraints. Should even a portion of this tonnage exit mainstream trading, the effective impact of new deliveries would be materially reduced, supporting a tighter and more constructive supply dynamic.

2026 has begun on a seasonally firm footing. Nevertheless, trade policy developments, evolving oil trade routes, and ongoing geopolitical tensions will continue to shape market conditions. In particular, any shifts in sanctions regimes, especially those related to Iran, Venezuela, and Russia, remain the principal swing factors for market direction.

Key Figures

USD million

Q1 2025

Q2 2025

Q3 2025

Q4 2025

Full year 2025

Income Statement

 

 

 

 

 

Operating revenue (Hafnia vessels and TC vessels)

340.3

346.6

366.5

368.4

1,421.8

Profit before tax

64.6

78.0

92.2

107.4

342.2

Profit for the period

63.2

75.3

91.5

109.7

339.7

Financial items

(13.9)

(8.1)

(13.3)

(9.3)

(44.6)

Share of profit from joint ventures

3.0

3.0

4.4

6.8

17.2

TCE income1

218.8

231.2

247.0

259.0

955.9

Adjusted EBITDA1

125.1

134.2

150.5

149.7

559.5

Balance Sheet

 

 

 

 

 

Total assets

3,696.4

3,669.9

3,570.1

3,811.9

3,811.9

Total liabilities

1,418.0

1,369.5

1,239.5

1,482.3

1,482.3

Total equity

2,278.4

2,300.4

2,330.7

2,329.6

2,329.6

Cash at bank and on hand2

188.1

194.0

132.5

103.6

103.6

Key financial figures

 

 

 

 

 

Return on Equity (RoE) (p.a.)3

11.1%

13.2%

15.9%

19.1%

14.8%

Return on Invested Capital (p.a.)4

9.6%

10.6%

12.8%

13.4%

11.2%

Equity ratio

61.6%

62.7%

65.3%

61.1%

61.1%

Net loan-to-value (LTV) ratio5

24.1%

24.1%

20.5%

24.9%

24.9%

For the 3 months ended 31 December 2025

LR2

LR1

MR6

Handy7

Total

Vessels on water at the end of the period8

6

26

52

24

108

Total operating days9

541

2,323

4,551

2,054

9,469

Total calendar days (excluding TC-in)

552

2,208

4,240

2,208

9,208

TCE (USD per operating day)1

33,163

30,986

26,307

24,006

27,346

Spot TCE (USD per operating day)1

35,307

31,473

27,305

24,211

27,976

TC-out TCE (USD per operating day)1

30,591

27,906

23,549

22,257

24,974

OPEX (USD per calendar day)10

8,503

9,171

8,933

8,029

8,748

G&A (USD per operating day)11

 

 

 

 

2,168

1

See Non-IFRS Measures Section below.

2

Excluding cash retained in the commercial pools.

3

Annualised

4

ROIC is calculated using annualised EBIT less tax.

5

Net loan-to-value is calculated as all debt (excluding debt relating to the pools), including finance lease debt, minus cash (excluding cash retained in the commercials pools), divided by broker vessel values (100% owned vessels) and the lower of the market value or purchase price of the Torm investment. The calculation of net loan-to-value does not include debt or values of vessels held through our joint ventures.

6

Inclusive of nine IMO II MR vessels. The two MRs classified as held for sale are excluded from vessels on the balance sheet, while they are included in the data for the 3 months ended 31 December 2025.

7

Inclusive of 18 IMO II Handy vessels.

8

Excluding six LR1s and four LR2s owned through 50% ownership in the Vista Shipping Joint Venture, two MRs owned through 50% ownership in the H&A Shipping Joint Venture and three IMO II MRs owned through 50% ownership in the Ecomar Joint Venture.

9

Total operating days include operating days for vessels that are time chartered-in. Operating days are defined as the total number of days (including waiting time) in a period during which each vessel is owned, partly owned, operated under a bareboat arrangement (including sale and lease-back) or time chartered-in, net of technical off-hire days. Total operating days stated in the quarterly financial information include operating days for TC Vessels.

10

OPEX includes vessel running costs and technical management fees.

11

G&A includes all expenses and is adjusted for cost incurred in managing external vessels.

Declaration of Dividend

Hafnia will pay a quarterly dividend of USD 0.1762 per share. The record date will be 6 March 2026.

For shares registered in the Euronext VPS Oslo Stock Exchange, dividends will be distributed in NOK with an ex-dividend date of 5 March 2026 and a payment date on, or about, 18 March 2026.

For shares registered in the Depository Trust Company, the ex-dividend date will be 6 March 2026, with a payment date on, or about, 13 March 2026.

Please see our separate announcement for additional details regarding the Company’s dividend.

Webcast and Conference Call

Hafnia will host a conference call for investors and financial analysts at 9:30 pm SGT/2:30 pm CET/8:30 am EST on 26 February 2026.

The investor presentation will be available via live video webcast via the following link: Click here to join Hafnia’s Investor Presentation on 26 February 2026 .

Meeting ID: 395 004 465 320 35

Passcode: 9La9JF7h

Download Teams | Join on the web

Dial in by phone: +45 32 72 66 19,,683452461# Denmark, All locations

Find a local number

Phone conference ID: 683 452 461#

A recording of the presentation will be available after the live event on the Hafnia Investor Relations Page: https://investor.hafnia.com/financials/quarterly-results/default.aspx.

About Hafnia

Hafnia is one of the world’s leading tanker owners, transporting oil, oil products and chemicals for major national and international oil companies, chemical companies, as well as trading and utility companies.

As owners and operators of around 200 vessels, we offer a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk. Hafnia has offices in Singapore, Copenhagen, Houston, and Dubai and currently employs over 4000 employees onshore and at sea.

Hafnia is part of the BW Group, an international shipping group involved in oil and gas transportation, floating gas infrastructure, environmental technologies, and deep-water production for over 80 years.

Non-IFRS Measures

Throughout this press release, we provide a number of key performance indicators used by our management and often used by competitors in our industry.

Adjusted EBITDA

“Adjusted EBITDA” is a non-IFRS financial measure and as used herein represents earnings before financial income and expenses, depreciation, impairment, amortization and taxes. Adjusted EBITDA additionally includes adjustments for gain/(loss) on disposal of vessels and/or subsidiaries, share of profit and loss from equity accounted investments, interest income and interest expense, capitalised financing fees written off and other finance expenses. Adjusted EBITDA is used as a supplemental financial measure by management and external users of financial statements, such as lenders, to assess our operating performance as well as compliance with the financial covenants and restrictions contained in our financing agreements.

We believe that Adjusted EBITDA assists management and investors by increasing comparability of our performance from period to period. This increased comparability is achieved by excluding the potentially disparate effects of interest, depreciation, impairment, amortization and taxes. These are items that could be affected by various changing financing methods and capital structure which may significantly affect profit/(loss) between periods. Including Adjusted EBITDA as a measure benefits investors in selecting between investment alternatives.

Adjusted EBITDA is a non-IFRS financial measure and should not be considered as an alternative to net income or any other measure of our financial performance calculated in accordance with IFRS. Adjusted EBITDA excludes some, but not all, items that affect profit/(loss) and these measures may vary among other companies. Adjusted EBITDA as presented below may not be comparable to similarly titled measures of other companies.

Reconciliation of Non-IFRS measures

The following table sets forth a reconciliation of Adjusted EBITDA to profit/(loss) for the financial period, the most comparable IFRS financial measure, for the periods ended 31 December 2025 and 31 December 2024.

 

For the 3 months ended 31 December 2025

USD’000

For the 3 months ended 31 December 2024

USD’000

For the 12 months ended 31 December 2025

USD’000

For the 12 months ended 31 December 2024

USD’000

Profit for the financial period

109,654

79,632

339,682

774,035

Income tax (benefit)/expenses

(2,283)

(61)

2,495

4,418

Depreciation charge of property, plant and equipment

49,231

52,404

201,702

214,308

Amortisation charge of intangible assets

108

108

427

803

Gain on disposal of assets

(9,467)

(12,999)

(12,236)

(28,520)

Share of profit of equity-accounted investees, net of tax

(6,846)

(601)

(17,190)

(20,515)

Interest income

(4,666)

(4,578)

(13,496)

(16,317)

Interest expense

12,940

13,645

49,768

52,375

Capitalised financing fees written off

400

2,720

2,069

Other finance expense

664

3,619

5,607

9,662

Adjusted EBITDA

149,735

131,169

559,479

992,318

Time charter equivalent (or “TCE”)

TCE (or TCE income) is a standard shipping industry performance measure used primarily to compare period-to-period changes in a shipping company’s performance despite changes in the mix of charter types (i.e., voyage charters and time charters) under which the vessels may be employed between the periods. We define TCE income as income from time charters and voyage charters (including income from Pools, as described above) for our Hafnia Vessels and TC Vessels less voyage expenses (including fuel oil, port costs, brokers’ commissions and other voyage expenses).

We present TCE income per operating day1, a non-IFRS measure, as we believe it provides additional meaningful information in conjunction with revenues, the most directly comparable IFRS measure, because it assists management in making decisions regarding the deployment and use of our Hafnia Vessels and TC Vessels and in evaluating their financial performance. Our calculation of TCE income may not be comparable to that reported by other shipping companies.

1 Operating days are defined as the total number of days (including waiting time) in a period during which each vessel is owned, partly owned, operated under a bareboat arrangement (including sale and lease-back) or time chartered-in, net of technical off-hire days. Total operating days stated in the quarterly financial information include operating days for TC Vessels.

Reconciliation of Non-IFRS measures

The following table reconciles our revenue (Hafnia Vessels and TC Vessels), the most directly comparable IFRS financial measure, to TCE income per operating day.

(in USD’000 except operating days and TCE income per operating day)

For the 3 months ended 31 December 2025

For the 3 months ended 31 December 2024

For the 12 months ended 31 December 2025

For the 12 months ended 31 December 2024

Revenue (Hafnia Vessels and TC Vessels)

368,419

352,817

1,421,831

1,935,596

Revenue (External Vessels in Disponent-Owner Pools)

224,543

180,044

860,078

933,051

Less: Voyage expenses (Hafnia Vessels and TC Vessels)

(109,454)

(119,257)

(465,957)

(544,317)

Less: Voyage expenses (External Vessels in Disponent-Owner Pools)

(80,154)

(83,995)

(329,566)

(332,802)

Less: Pool distributions for External Vessels in Disponent-Owner Pools

(144,389)

(96,049)

(530,512)

(600,249)

TCE income

258,965

233,560

955,874

1,391,279

Operating days

9,469

10,293

37,922

42,160

TCE income per operating day

27,346

22,692

25,206

33,000

Revenue, voyage expenses and pool distributions in relation to External Vessels in Disponent-Owner Pools nets to zero, and therefore the calculation of TCE income is unaffected by these items:

(in USD’000 except operating days and TCE income per operating day)

For the 3 months ended 31 December 2025

For the 3 months ended 31 December 2024

For the 12 months ended 31 December 2025

For the 12 months ended 31 December 2024

Revenue (Hafnia Vessels and TC Vessels)

368,419

352,817

1,421,831

1,935,596

Less: Voyage expenses (Hafnia Vessels and TC Vessels)

(109,454)

(119,257)

(465,957)

(544,317)

TCE income

258,965

233,560

955,874

1,391,279

Operating days

9,469

10,293

37,922

42,160

TCE income per operating day

27,346

22,692

25,206

33,000

‘TCE income’ as used by management is therefore only illustrative of the performance of the Hafnia Vessels and the TC Vessels; not the External Vessels in our Pools.

For the avoidance of doubt, in all instances where we use the term “TCE income” and it is not succeeded by “(voyage charter)”, we are referring to TCE income from revenue and voyage expenses related to both voyage charter and time charter.

Forward-Looking Statements

This press release and any other written or oral statements made by us or on our behalf may include “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include statements concerning our intentions, beliefs or current expectations concerning, among other things, the financial strength and position of the Group, operating results, liquidity, prospects, growth, the implementation of strategic initiatives, as well as other statements relating to the Group’s future business development, financial performance and the industry in which the Group operates, which are other than statements of historical facts or present facts and circumstances. These forward-looking statements may be identified by the use of forward-looking terminology, such as the terms “anticipates”, “assumes”, “believes”, “can”, “contemplate”, “continue”, “could”, “estimates”, “expects”, “forecasts”, “intends”, “likely”, “may”, “might”, “plans”, “should”, “potential”, “projects”, “seek”, “target”, “will”, “would” or, in each case, their negative, or other variations or comparable terminology.

The forward-looking statements in this press release are based upon various assumptions, including without limitation, management’s examination of historical operating trends, data contained in our records and data available from third parties. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot guarantee prospective investors that the intentions, beliefs or current expectations upon which its forward-looking statements are based will occur.

Other important factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements due to various factors include, but are not limited to:

  • general economic, political, security, and business conditions, including the development of the ongoing war between Russia and Ukraine and the conflict between Israel and Hamas, disruptions in the Red Sea, sanctions and other measures;

  • general chemical and product tanker market conditions, including fluctuations in charter rates, vessel values and factors affecting supply and demand of crude oil and petroleum products or chemicals;

  • the imposition by the United States, China, EU and other countries of tariffs and other policies and regulations affecting international trade, including fees and import and export restrictions;

  • changes in expected trends in recycling of vessels;

  • changes in demand in the chemical and product tanker industry, including the market for LR2, LR1, MR and Handy chemical and product tankers;

  • competition within our industry, including changes in the supply of chemical and product tankers;

  • our ability to successfully employ the vessels in our Hafnia Fleet and the vessels under our commercial management;

  • changes in our operating expenses, including fuel or cooling down prices and lay-up costs when vessels are not on charter, drydocking and insurance costs;

  • changes in international treaties, governmental regulations, tax and trade matters and actions taken by regulatory authorities;

  • potential disruption of shipping routes and demand due to accidents, piracy or political events;

  • vessel breakdowns and instances of loss of hire;

  • vessel underperformance and related warranty claims;

  • our expectations regarding the availability of vessel acquisitions and our ability to complete the acquisition of newbuild vessels;

  • our ability to procure or have access to financing and refinancing;

  • our continued borrowing availability under our credit facilities and compliance with the financial covenants therein;

  • fluctuations in commodity prices, foreign currency exchange and interest rates;

  • potential conflicts of interest involving our significant shareholders;

  • our ability to pay dividends;

  • technological developments;

  • the occurrence, length and severity of epidemics and pandemics and the impact on the demand for transportation of chemical and petroleum products;

  • the impact of increasing scrutiny and changing expectations from investors, lenders and other market participants with respect to environmental, social and governance initiatives, objectives and compliance;

  • other factors that may affect our financial condition, liquidity and results of operations; and

  • other factors set forth in “Item 3. – Key Information – D. Risk Factors” of Hafnia’s Annual Report on Form 20-F, filed with the U.S. Securities and Exchange Commission on 30 April 2025

Because of these known and unknown risks, uncertainties and assumptions, the outcome may differ materially from those set out in the forward-looking statements. These forward-looking statements speak only as at the date on which they are made. Hafnia undertakes no obligation to publicly update or publicly revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Mikael Skov, CEO Hafnia

+65 8533 8900

KEYWORDS: Singapore Southeast Asia Asia Pacific

INDUSTRY KEYWORDS: Chemicals/Plastics Maritime Logistics/Supply Chain Management Oil/Gas Transport Manufacturing Energy

MEDIA:

Logo
Logo

CMB.TECH ANNOUNCES Q4 2025 RESULTS – EIGHT VLCCS SOLD AT STELLAR PRICES

CMB.TECH ANNOUNCES Q4 2025 RESULTS

EIGHT VLCCS SOLD AT STELLAR PRICES

ANTWERP, Belgium, 26 February 2026 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO)
reported its unaudited financial results today for the fourth quarter ended 31 December 2025.

HIGHLIGHTS

Financial highlights:

  • Profit for the period of USD 90.1 million in Q4 2025. EBITDA for the same period was USD 322 million.
  • CMB.TECH’s contract backlog increased by USD 304 million to USD 3.05 billion with the addition of 5 x 5-year charters for Capesizes and a 3-year contract for a CSOV.
  • Declaration of an interim dividend of USD 0.16 per share.
  • Over the course of Q4 2025 and Q1 2026, the company has fully repaid the bridge loan facility that was originally raised to finance the acquisition of a large stake in Golden Ocean 

Fleet highlights: 

  • Delivery of 6 newbuilding vessels (Q4 + quarter to date):
    • VLCCs: Atrebates, Eburones
    • Chemical tankers: Bochem Callao
    • CSOV: Windcat Amsterdam
    • CTV: FRS Windcat 62, FRS Windcat 61
  • Previously announced sale of 8 VLCCs: Daishan (2007, 306,005 dwt), Hirado (2011, 302,550 dwt), Ilma (2012, 314,000 dwt), Ingrid (2012, 314,000 dwt), Hojo (2013, 302,965 dwt), Dia (2015, 299,999 dwt), Antigone (2015, 299,421 dwt), and Aegean (2016, 299,999 dwt).
  • Previously announced sale of Capesize vessels Golden Magnum (2009, 179,790 dwt), and Belgravia (2009, 169,390 dwt).

Corporate highlights:

  • Sale of stake in Tankers International Pool, closed on 27 January 2026.
  • CMB.TECH is investing in the Chinese ammonia supply chain.
  • Management Board changes: resignation of Mr. Benoit Timmermans

For the fourth quarter of 2025, the company realised a net gain of USD 90.1 million or USD 0.31 per share (fourth quarter 2024: a net gain of USD 93.1 million or USD 0.48 per share). EBITDA (a non-IFRS measure) for the same period was USD 322.1 million (fourth quarter 2024: USD 180.4 million).

Commenting on the Q4 results, Alexander Saverys (CEO) said:

“Tanker markets continue to defy gravity due to a mix of shifting trade patterns, modest newbuilding deliveries and a particularly active tanker owner/operator who is adding fuel to the fire. Dry bulk freight rates have also held up very well during Q4 and well into Q1. With two CSOVs delivered to our fleet, we are starting to generate meaningful cash flows in the offshore supply markets. The versatile nature of our ships allows us to serve wind and oil and gas customers alike.

We have used this very strong market back-drop to sell some of our older vessels at stellar prices, and fixed multiple long-term charter contracts at attractive rates. We will use the proceeds to decrease our leverage, strengthen our balance sheet and pay dividends. The repayment of the Golden Ocean bridge – less than six months after the merger – is testimony to our capability to execute large transactions swiftly, efficiently and in a disciplined manner.”


Key figures

                       
  The most important key figures (unaudited) are:                    
                       
  (in thousands of USD)     Fourth Quarter 2025   Fourth Quarter 2024   YTD 2025   YTD 2024  
                       
  Revenue             589,123           226,029           1,666,223           940,246          
  Other operating income             1,361           8,254           29,613           50,660          
                       
  Raw materials and consumables             (3,769)           (1,576)           (10,265)           (3,735)          
  Voyage expenses and commissions             (128,169)           (42,692)           (362,155)           (174,310)          
  Vessel operating expenses             (128,067)           (52,817)           (420,409)           (199,646)          
  Charter hire expenses             (415)           (3)           (3,124)           (138)          
  General and administrative expenses             (52,813)           (24,616)           (143,284)           (77,766)          
  Net gain (loss) on disposal of tangible assets             49,489           71,114           192,564           635,017          
  Depreciation and amortisation             (114,526)           (43,911)           (387,968)           (166,029)          
  Impairment losses             (2,081)           (1,847)           (5,354)           (1,847)          
                       
  Net finance expenses             (110,997)           (47,096)           (404,630)           (130,650)          
  Share of profit (loss) of equity accounted investees             (2,599)           (1,418)           (882)           920          
  Result before taxation             96,537           89,421           150,329           872,722          
                       
  Income tax benefit (expense)             (6,476)           3,709           (10,185)           (1,893)  
  Profit (loss) for the period             90,061           93,130           140,144           870,829          
                       
  Attributable to:                    
  Owners of the Company             90,061           93,130           161,698           870,829          
  Non-controlling interest             —           —           (21,554)           —          
                       
                       

                     
  Earnings per share:                  
                     
  (in USD per share)   Fourth Quarter 2025   Fourth Quarter 2024   YTD 2025   YTD 2024  
                     
  Weighted average number of shares (basic) *           290,169,769           194,216,835                   229,443,392           196,041,579          
  Basic earnings per share           0.31           0.48                   0.61           4.44          
                     
                     
  • The number of shares issued on 31 December 2025 is 315,977,647. However, the number of shares excluding the owned shares held by CMB.TECH at 31 December 2025 is 290,169,769.

                       
  EBITDA reconciliation (unaudited):                    
                       
  (in thousands of USD)     Fourth Quarter 2025   Fourth Quarter 2024   YTD 2025   YTD 2024  
                       
  Profit (loss) for the period             90,061           93,130                   140,144           870,829          
  + Net finance expenses             110,997           47,096                   404,630           130,650          
  + Depreciation and amortisation             114,526           43,911                   387,968           166,029          
  + Income tax expense (benefit)             6,476           (3,709)                   10,185           1,893          
  EBITDA (unaudited)             322,060           180,428                   942,927           1,169,401          
                       

                       
  EBITDA per share:                    
                       
  (in USD per share)     Fourth Quarter 2025   Fourth Quarter 2024   YTD 2025   YTD 2024  
                       
  Weighted average number of shares (basic)             290,169,769           194,216,835                   229,443,392           196,041,579          
  EBITDA             1.11           0.93                   4.11           5.97          
                       
                       

All figures, except for EBITDA, have been prepared under IFRS as adopted by the EU (International Financial Reporting Standards) and have not been audited nor reviewed by the statutory auditor.

During the quarter, several nonrecurring items affected the company’s financial performance. The company fully repaid the bridge loan facility that had originally been raised to finance the acquisition of a large stake in Golden Ocean, resulting in a one-off charge of USD 13.6 million, mainly related to arrangement and success fees. Furthermore, following the various refinancings completed in Q4 (which included a repayment of more than USD 700 million under the USD 2 billion facility) approximately USD 11 million in arrangement fees were expensed. In addition, 28 reflagging operations were carried out in Q4, temporarily increasing operating expenses by approximately USD 2.9 million. Reflagging of vessels is required in view of the contemplated cross-border merger of CMB.TECH Bermuda (holding company of ex-Golden Ocean group) with CMB.TECH Belgium. Other non-recurring costs (SG&A and tax) accounted for USD 15 million.


Interim dividend

CMB.TECH has declared an interim dividend of USD 0.16 per share, which is expected to be paid on or about 27 April 2026.

The timing of the distribution of this interim dividend is as follows:

COUPON 44 Ex-dividend date Record date Payment date
Euronext 14 April 2026 15 April 2026 22 April 2026
NYSE 15 April 2026 15 April 2026 22 April 2026
OSE 14 April 2026 15 April 2026 On or about 27 April 2026


TCE

The average daily time charter equivalent rates (TCE, a non IFRS-measure) can be summarised as follows:

 

 

Q4 2025 Q4 2024 Quarter-to-Date Q1 2026
USD/day USD/day USD/day Fixed %
DRY BULK VESSELS
Newcastlemax average spot rate(1) 34,886 29,800 30,673 80.0%
Newcastlemax average time charter rate 21,284      
Capesize average rate(1) 30,137   26,725 72.0%
Panamax/Kamsarmax average spot rate(1) 17,337   13,279 66.0%
Panamax/Kamsarmax average time charter rate 13,207      
TANKERS
VLCC average spot rate (2) 74,842 37,400 74,465 78.0%
VLCC average time charter rate(3) 45,582 46,300    
Suezmax average spot rate(1) (3) 64,543 38,300 61,809 87.0%
Suezmax average time charter rate 33,613 31,800    
CONTAINER VESSELS
Average time charter rate 29,378 29,378    
CHEMICAL TANKERS
Average spot rate(1) (2) 20,887 24,500  17,878  N/A
Average time charter rate 19,306 19,306    
 
OFFSHORE WIND
CSOV Average time charter rate 108,046   69,900 50.0%
CTV Average time charter rate 2,883 2,900 2,472 68.8%


1)

Reporting load-to-discharge, in line with IFRS 15
, net of commission


(


2


)

CMB.TECH owned ships in
TI Pool or Stolt Pool
(excluding technical off hire days)


(


3


)

Including profit share where applicable


CORPORATE UPDATE


Sale TI Pool

CMB.TECH has sold its share in the Tankers International (TI) Pool to International Seaways (INSW), closed on 27 January 2026. Our tanker division Euronav was one of the founding fathers of TI and has supported the company throughout its successful history. With the sale of a large part of our VLCC fleet to Frontline in 2024 and the recent sale of some older tankers more recently, it was the right moment to exit TI. Under the new full ownership of INSW, the company and its employees will remain a strong reference in the crude oil tanker markets.


Andefu

CMB.TECH previously announced that the company is investing in the Chinese ammonia supply chain. CMB.TECH has signed an off-take agreement for green ammonia produced by CEEC Hydrogen Energy (“CEEC”) in Jilin Province and owns a minority share in privately owned Jiangsu Andefu Energy Technology Co., Ltd. (“Andefu”) one of China’s largest ammonia supply chain companies. This creates an industrial partnership between two companies supporting maritime decarbonisation and the development of a green ammonia supply infrastructure.

A subsidiary of Andefu, Jiangsu Andefu Storage Co., Ltd., is currently constructing a 49,000 m³ low-temperature ammonia storage tank in Nanjing, providing critical hub capacity for ammonia distribution and future marine fuel applications. The storage tank is scheduled to be commissioned in Q1 2026. In addition, Andefu, in cooperation with CEEC, will build an ammonia storage terminal into operation in Panjin in the second half of 2027, significantly enhancing China’s large-scale green ammonia logistics and supply capabilities. Andefu is also advancing ship-to-ship (STS) ammonia bunkering operations, targeting commercial deployment in 2026, to support the emerging global ammonia-fuelled shipping fleet together with CMB.TECH.


Golden Ocean bridge

Over the course of Q4 2025 and Q1 2026, the company has fully repaid the bridge loan facility that was originally raised to finance the acquisition of a controlling stake in Golden Ocean while continuing the integration workstreams related to the Golden Ocean merger. This resulted in a one‑off charge of USD 13.6 million, primarily reflecting arrangement and success fees. No additional costs related to these activities are anticipated in the 2026 financial year. The early repayment in full of the USD 1.4 billion Golden Ocean bridge loan facility is projected to yield approximately USD 41.9 million in interest savings over the 2026 reporting period.


Management Board change

Mr. Benoit Timmermans has decided to resign as member of the Management Board of CMB.TECH with effect as of 1 May 2026. Mr. Benoit Timmermans joined the Management Board of CMB.TECH as Chief Strategy Officer and has assisted the company in the transition from a pure-play crude oil tanker player to a large and diversified maritime group. For the time being, Mr. Timmermans will not be replaced. His responsibilities will be taken over by the current members of the Management Board.


CMB.TECH FLEET DEVELOPMENTS

Commercial contracts

CMB.TECH’s contract backlog increased by USD 304 million to USD 3.05 billion:

5 Capesizes were fixed for charter contracts of 5 years each. These will commence in the coming months.

  • Mineral Ajisai (2014, 180,600 dwt)
  • Mineral Sakura (2014, 182,480 dwt)
  • Mineral Cumulus (2018, 180,600 dwt)
  • Mineral Calvus (2018, 180,520 dwt)
  • Mineral Incus (2018, 180,510 dwt)

The CSOV Windcat Amsterdam was fixed for 3 years as from 1 April 2026.

Sales

Following vessels were delivered to new owners in Q4 2025 – generating a total capital gain of approximately USD 49.2 million:

  • VLCC Dalma (2007, 306,543 dwt) – capital gain of USD 26.4 million
  • Capesize Battersea (2009, 169,390 dwt) – capital gain of USD 2.4 million
  • Capesize Golden Zhoushan (2011, 175,834) was delivered to its new owner during Q4 2025 – no capital gain 
  • Suezmax Sofia (2010, 165,000 dwt) – capital gain of USD 20.4 million

Following vessels will be delivered to new owners in Q1 2026:

  • Capesize vessels Golden Magnum (2009, 179,790 dwt), and Belgravia (2009, 169,390 dwt) – capital gain of approximately USD 8.1 million in Q1 2026, based on the net sales price and book values
  • Six VLCCs: Daishan (2007, 306,005 dwt), Hirado (2011, 302,550 dwt), Hojo (2013, 302,965 dwt), Dia (2015, 299,999 dwt), Antigone (2015, 299,421 dwt), and Aegean (2016, 299,999 dwt) – capital gain of approximately USD 261.1 million in Q1 2026, based on the net sales price and book values.

Following vessels will be delivered to new owners in Q2 2026:

  • Two VLCCs: Ilma (2012, 314,000 dwt) and Ingrid (2012, 314,000 dwt) – capital gain of approximately USD 98.2 million in Q2 2026, based on the net sales price and book values.

Newbuilding deliveries

Delivery date Type of vessel Name
10 November 2025 VLCC Atrebates (2025, 319,000 dwt)
12 November 2025 CTV Windcat 61
12 December 2025 CTV Windcat 62
19 December 2025 CSOV Windcat Amsterdam
12 January 2026 VLCC Eburones (2026, 319,000 dwt)
13 January 2026 Chemical tanker Bochem Callao (2026, 25,000 dwt)


MARKET & OUTLOOK

Bocimar – Dry-Bulk Market

1

Following a slow first half in 2025, imports of iron ore to mainland China rebounded strongly in H2 2025, ending the year at 1,327 million tonnes, driven by stockpiling, a strengthening yuan which made imports more cost-effective, and targeted stimulus aimed at stabilising construction and manufacturing activity. The expansion was primarily fuelled by heightened trade flows between major iron ore producing regions and key consuming markets: Australia, Brazil, Sub-Saharan Africa, and Canada significantly increased shipments to mainland China, while Brazil and Oman boosted their shipments to India, and Liberia expanded its supply to Europe. Chinese steel exports also hit a record 11.3 million tons in December 2025, raising for the full year by 7.5% to 119.2 million tons. Capesize spot earnings in Q4 2025 averaged about 27,120 USD/day (34% higher than the 10-year Q4 average). Panamax spot earnings in Q4 2025 averaged about 14,880 USD/day (6% below the 10-year Q4 average).

In China, portside inventories are on a raising trend, reaching 151.6 million tonnes by the end of 2025, just below all-time highs. While elevated stocks can slow the rhythm of spot cargoes as mills draw down port inventories first, the iron ore market remains fundamentally supported. Despite sustained policy initiatives aimed at improving domestic resource security, China’s local iron-ore mines continue to fall short of official production objectives. Output of iron-ore concentrate decreased y-o-y 2025 by 3.2%. This decline underlines persistent challenges, including diminishing ore grades, fragmented industry ownership, and slow rates of capital investment. China’s domestic ore, with its low iron content and high impurities, cannot meet the requirements of modern blast-furnace operations on its own. To achieve stable furnace performance, steelmakers blend higher-grade imported fines with domestic material – raising the effective grade, improving fuel efficiency, and supporting consistent output. Hence, high-grade seaborne imports of iron ore are essential for keeping China’s steel production efficient, cost-effective, and technically reliable. In addition, on the steel side, the introduction of export licensing from 1 January 2026 marks a clear change in how outbound steel trade is managed and exports switched from quantity to quality. Higher quality steel exports further reconfirm the requirement of seaborne high-grade iron ore sourcing and hence also further support the ton-mile story for the Capesize and Newcastlemax segment.

Structurally longer trade flows and high-grade substitution support tonne-mile demand. The ramp-up of the Simandou project in Guinea—targeting 120 million tonnes/year by 2028—will introduce high-grade ore flows (65% Fe) that are structurally longer than Australia-to-China shipments. Initial deliveries of 200,000 tonnes have already reached China, with total 2026 production expected at 15–20 million tonnes. Next to Simandou, South Buchanan/Liberia (Mittal) will increase iron ore exports from 5 to15 million tonnes in 2026.

Overall, iron ore discharge to mainland China in 2026 is projected to rise to 1,361 million tonnes (up 2.5% y-o-y), underpinned by supportive fiscal and monetary policies, a strong yuan, and declining domestic output. However, there is potential for reduced shipments in the first quarter of 2026, as demand from Chinese steel mills may soften during the Lunar New Year holiday. Global seaborne iron ore shipments are projected to increase by 1.9% y-o-y in 2026, reaching 1,799 million tonnes.

Bauxite has become an increasingly important cargo stream for Capesize vessels (roughly 16% of Capesize tonne-mile demand), offsetting weakness in coal volumes. Guinea’s bauxite shipments have been outperforming its historical volumes, with 47 million tonnes shipped in Q4 2025, up approximately 7 million tonnes y-o-y, with 91% of the volume shipped to mainland China. We expect this buoyancy to persist in 2026, even though with a lesser degree, with Q1 2026 volume to be up 3 million tonnes y-o-y from Guinea. Mainland China’s bauxite arrivals are expected to expand by 9 million tonnes during the year in line with the increased domestic demand for inputs feeding into the aluminium industry. However, this is considerably less than the 40 million tonnes surge experienced in 2025. Domestic bauxite inventories have been historically high along with an oversupply of alumina and with the government mandated production cap on aluminium at 45 million tonnes, the expected increase in additional bauxite demand will likely moderate relative to last year. However, notably, capacity expansion at Chinese-owned Chalco-Boffa Mining site in Guinea should continue facilitating additional supply between the two trade partners.

While bauxite and iron ore continue to be positive contributors to the dry bulk market, the coal trade is trending in the opposite direction. Demand from mainland China for thermal coal took a hit over 2025 as the expansion in renewable capacity and generation increasingly ate into coal-fired generation, and rising domestic output displaced seaborne supply. We may have already seen the peak of coal consumption in mainland China as over 2025 we have seen coal-fired generation drop, as the growth in electricity generation takes on a more restrained pace and renewable additions continue their fierce 25-30% y-o-y growth rate. The outlook for the beginning of 2026 remains flat, as the market remains fundamentally weak in terms of coal demand, save for some import activity from buyers in mainland China looking to fulfil their requirements for the colder than expected winter months.

Agribulk shipments rose 2.5% y-o-y 2025 followed by a 1.5% growth expected in 2026. US shipments are expected to rise on the back of healthy corn production in addition to revival in soybean trade with mainland China (revival after interruption of exports since May due to tariff war). In Q1 2026 to date, an early start to grain season has supported the Kamsarmax market which in turn supports the other dry bulk segments during the low season

The Capesize and Newcastlemax orderbook currently stands at 12.4% of the active fleet. 36% or 586 vessels are over 15 years old and are increasingly uneconomical to operate amid rising environmental compliance costs. The Panamax and Kamsarmax orderbook currently stands at 15.16% – with 32% or 900 vessels over 15 years old. The market remains relatively balanced, though growth drivers are strongly skewed in favour of Capesizes: estimated demand growth in 2026 of 2.7%, in billion tonne miles with a net fleet growth of 2.3%. (Panamax estimated demand growth in 2026 of 3.2%, in billion tonne miles with a net fleet growth of 4.7%)

Bocimar has 36 (+10NB) Newcastlemaxes on the water (average age 3.2y), 37 Capesize vessels on the water (average age 11.2), 30 Kamsarmax/Panamax vessels on the water (average age 6.9y), and two 5,000 dwt dry-bulk coasters on order.

Q4 2025 Performance Highlights:

  • Newcastlemax: Q4 2025 TCE actuals at 34,886 USD/day, outperforming 5TC BCI by 7,455 USD/day net of commissions. Q1 2026 TCE quarter to date rates at 30,673 USD/day (80% fixed).
  • Capesize: Q4 2025 TCE actuals at 30,137 USD/day, outperforming 5TC BCI by 2,706 USD/day net of commissions. Q1 2026 TCE quarter to date rates at 26,725 USD/day (72% fixed).
  • Kamsarmax/Panamax: Q4 2025 TCE actuals at 17,337 USD/day, outperforming 5TC BPI-82 by 2,109 USD/day net of commissions. Q1 2026 TCE quarter to date rates at 13,207 USD/day (66% fixed).

Euronav – Tanker Markets

2

Both OPEC and non-OPEC supply ended 2025 at elevated levels. Over the full year, non-OPEC crude oil and condensate supply averaged 1.2 mb/d higher than in 2024. In addition, since March 2025, OPEC’s production quota increased by 2.9 mb/d, while actual output rose by 0.5 mb/d over the same period.

The crude oil tanker market strengthened markedly in late 2025, with the VLCC and Suezmax segments recording their highest earnings in several years. Key drivers were crude oil supply growth and increased volumes of oil-on-water. During 2025, global inventories of crude oil and refined products rose by 529 million barrels, reflecting oil that has been produced but not yet consumed, including in-transit volumes. China continued stockpiling in line with its mandate, hitting a record high crude import of 13.2 mb/d in December 2025. China’s crude inventories built at near-record levels in December, rising by 31.3 million barrels. Newly implemented sanctions also reduced the effectiveness of the non-compliant tanker fleet.

The resulting tightening in effective fleet capacity pushed freight rates significantly higher. VLCC spot earnings in Q4 2025 averaged about 102,414 USD/day, more than double the 10-year Q4 average of 47,986 USD/day. Suezmax spot earnings in Q4 2025 averaged 77,370 USD/day, almost double the 10-year Q4 average of 43,507 USD/day. By mid-Q4, VLCC spot rates consistently exceeded 100,000 USD/day, reflecting a limited supply of available tonnage.

OPEC and non-OPEC supply growth also sets up the market for a surplus in the 2026 crude oil-only balance. Agencies differ in their views on the size of this surplus: the IEA estimates a +4.00 mb/d balance, the EIA +2.30 mb/d, while OPEC projects equilibrium. As a result, seaborne crude oil demand is currently driven less by end-consumer consumption and more by inventory accumulation in China and by OPEC+ maintaining market share over price. If these trends continue at similar rates, global inventories could approach the Covid-era peak of May 2020 by the end of 2026, supporting seaborne crude transportation through the remainder of 2026. A continued surplus would pressure oil prices and encourage further inventory building, which has historically supported tanker rates in the short term. Over time, however, sustained lower prices would increase the likelihood of OPEC+ production cuts, which would reduce tanker demand.

Higher charter rates have been accompanied by higher asset values. Second-hand VLCC and Suezmax prices are at their highest levels in 20 years. Clarksons data shows that ten-year-old VLCC values increased from approximately USD 43 million in 2020 to over USD 90 million by the end of 2025 (Suezmax 10-year-old: USD 28 million in 2020 to over USD 64 million by the end of 2025).

Geopolitics continue to influence crude trade patterns. Russia’s war in Ukraine and related sanctions have redirected exports from Europe toward Asia and led to complex compliance and non-compliance practices that reshape tanker flows and lengthen shipping routes. Instability in Iran and around the Strait of Hormuz presents ongoing risk to a key global chokepoint. Red Sea disruptions have reduced traffic through important maritime routes, forcing detours and increasing transport costs. Political pressure on Venezuelan exports and shadow fleet activity continue to alter Atlantic Basin trade, while China’s role as a major buyer of sanctioned barrels means that changes in sanction policy or enforcement could quickly affect tanker demand and deployment. These dynamics remain fluid and complex, making short-term impacts on the compliant tanker fleet difficult to predict.

Market fundamentals indicate continued medium-term strength into H1 2026. Fleet supply growth is accelerating with a Suezmax OB/F of 22.1%, and VLCC OB/F of 18.8%. However, approximately 18–19% of the existing fleet are aged 20 years or older (40%>15 years), implying elevated scrapping potential (once market rates cool down and non-compliant crude tankers become idle).

Euronav has 3 (+3NB) VLCCs (average age 4.9y) and 17 (+2NB) Suezmaxes (average age 6.9y) on the water. Q3 2025 Performance Highlights:

  • VLCC: actual Q4 TCE for VLCC of 74,842 USD/day and actual Q1 2026 quarter-to-date of 74,465 USD/day (78% fixed)
  • Suezmax: actual Q4 TCE for Suezmax of 64,543 USD/day and actual Q1 2026 quarter-to-date of 61,809 USD/day (87% fixed)

 Delphis – Container Markets3

Container freight markets remain supported but cyclical risks are further building. Spot rates are moderate overall, underpinned by firm pre–Lunar New Year demand. The SCFI stood just below 1,500 in mid-January—around 40% below the elevated 2024 average but still ~50% above 2023 levels.

Supply growth is set to outpace demand over the medium term. Containership fleet capacity is projected to expand with 4.5% in 2026, accelerating to 6.4% by 2027, materially above expected volume growth and likely to drive rate normalisation. Container trade growth is forecasted to slow to 2.5% this year amid tariff headwinds—particularly on the Transpacific—and with Asia–Europe and secondary trades moderating from the exceptionally strong levels seen in 2025. A steadier 3.0% growth profile is forecasted for 2027.

Red Sea disruption remains the key swing factor. Rerouting is currently adding 11.0% to global TEU-mile demand and is the main uphold to earnings and utilisation. Any de-escalation would remove this support and accelerate the move toward materially weaker market conditions. While carriers may respond through capacity management and higher demolition, the risk is skewed to a more challenging rate environment ahead, with another wave of supply (>4m TEU on order for 2028) building in the background.

CMB.TECH’s 4 x 6,000 TEU (average age 1.8y) and 1 NB 1,400 TEU container vessels are all employed under 10 to 15-year time charter contracts.

Bochem – Chemical Markets

4

The chemical tanker markets have shown signs of gradual easing through-out 2025, albeit from a robust starting point earlier in 2024. Demand remains closely tied to global GDP growth. Seaborne trade volumes appear to have been negative in 2025 (-0.8% billion tonne-miles), as tariff volatility weighed on arbitrage activity.

The global chemical tanker orderbook now stands at 18.8% of the existing fleet. The current fleet has an average age of 18 years, with 26% of vessels aged 20 years or older, suggesting that much of the orderbook should primarily serve as replacement tonnage. Nevertheless, the risk of oversupply could emerge in 2026 to 2027, depending on demand growth. 2025 net fleet growth was 3.7%, accelerating to 9.7% in 2026 and 5.9% in 2027, before easing to below 3% in 2028, assuming no additional ships are ordered.

Low ton-mile growth for 2026 and 2027 of 0.8% and 0.9%, respectively, and swing product tankers continue to be a factor in effective supply, although their impact is currently limited. While a strong product tanker market could reduce effective fleet growth somewhat, we do not expect this to be sufficient to halt the anticipated downtrend in earnings.

Bochem 25,000 DWT chemical tankers fleet comprises out of 8 delivered vessels, and 8 NB vessels (average age <1y). They are employed under a 10-year time charter (6 vessels), under a 7-year time charter (6 vessels), and in a spot pool (2 vessels). Q4 2025 performance highlights:

  • Bochem achieved TCE Q4 2025 of USD 20,887 per day USD/day (spot pool)
  • Q1 2026 spot rates to-date: USD 17,878 per day (spot pool)

Windcat – Offshore Energy Markets

5

Nine North Sea countries have signed a binding offshore wind investment pact, with the UK, Germany and the Netherlands—Europe’s three core offshore wind markets—all participating. Under the agreement, governments commit to accelerating offshore wind deployment through large-scale, cross-border projects and coordinated infrastructure planning. The countries had previously pledged to develop 300GW of offshore wind by 2050; the new pact reportedly earmarks 100GW of this capacity for joint development. For context, Europe currently has only 36GW of installed offshore wind, implying a step-change in the medium- to long-term build-out trajectory. Reports suggest up to 20GW of jointly developed capacity could already be underway by 2030. The joint declaration said the governments would also step up their efforts to increase financing for wind projects, potentially including through guarantees from the EU budget, and subsidy frameworks like CfD (contracts for difference).

From a vessel market perspective, this confirmation is important. It gives confidence in the medium-term pipeline and validates the scale of construction and O&M demand, following a period where negative headlines through 2025 had raised concerns around project progression.

CSOV demand strengthened through Q4 2025, allowing a large portion of the fleet to secure employment through the winter (off)season. In addition to near-term activity, a material increase is noticeable in contract opportunities for the 2026 season and beyond, with a significant share of projects still unfixed. While some vessel availability is expected in Q1 2026, utilisation should rise sharply from April, with the majority of the European CSOV fleet effectively committed. Incremental availability is not expected to return before late Q3 2026.

Rates and earnings momentum is building in the CSOV market. Owners with open capacity in 2026 are well positioned to benefit from a tightening market, a trend already reflected in rate indications for next year’s work. The supply–demand balance is further supported by rising oil & gas-related demand (including outside Europe) and a sharp slowdown in speculative newbuild ordering over the past 12 months.

Medium-term setup remains constructive. The reduction in new orders should moderate fleet growth from 2028 onwards, while underlying CSOV demand from offshore wind and oil & gas is expected to continue expanding.

In general, we see orders for offshore wind vessels reducing, including CSOVs: 2024 #19 NB orders, and 2025 #9 NB orders – with 16 C/SOVs delivered throughout 2025, while 15 CSOVs are scheduled to be delivered throughout 2026. CSOV fleet stands today at 71 vessels versus an orderbook of 50 vessels (OB/F 70.4%).

CTV fleet utilisation remained high at the start of Q4 2025, although a number of vessels, particularly smaller and 12-pax units, were redelivered to owners in October and November as seasonal activity tapered. Spot chartering during the quarter was limited to minor crew-change and cargo-transfer work. That said, a meaningful volume of 2026 season requirements entered the market, several of which have already been fixed, with additional fixtures expected early in Q1, improving forward revenue visibility.

CTV fleet stands at 731 units with 101 units on order (OB/F 13.8%). As newbuilding levels are relatively modest, it is not expected that supply will exceed demand and hence market conditions are likely to remain familiar (including the typical seasonal patterns).

Windcat has 2 (+5NB) CSOVs, and 59(+4NB) CTVs (average age 9.43y). Q4 2025 performance highlights:

  • CSOVs: achieved TCE Q4 2025 of USD 108,046 per day. CSOV Q1 2026 spot rates to-date: so far 50.0% fixed at USD 69,900 per day
  • CTVs: achieved TCE Q4 2025 of USD 2,883 per day. CTV Q1 2026 spot rates to-date: so far 68.8% fixed at USD 2,472 per day


CONFERENCE CALL


The call will be a webcast with an accompanying slideshow. You can find the details of this conference call below and on the “Investor Relations” page of the website. The presentation, recording & transcript will also be available on this page.

Webcast Information  
Event Type:  Audio webcast with user-controlled slide presentation
Event Date: 26 February 2026
Event Time: 8 a.m. EST / 2 p.m. CET
Event Title:  “Q4 2025 Earnings Conference Call”
Event Site/URL:   https://events.teams.microsoft.com/event/5ed65c96-e28b-44be-a75a-6ca20467b7eb@d0b2b045-83aa-4027-8cf2-ea360b91d5e4

To attend this conference call, please register via the following link.

Telephone participants who are unable to pre-register may dial in to the respective number of their location (to be found here). The Phone conference ID is the following: 273 707 348#


Publication final year results – 31 March 2026

About CMB.TECH

CMB.TECH (all capitals) is one of the largest listed, diversified and future-proof maritime groups in the world with a combined fleet of about 250 vessels: dry bulk vessels, crude oil tankers, chemical tankers, container vessels, offshore energy vessels and port vessels. CMB.TECH also offers hydrogen and ammonia fuel to customers, through own production or third-party producers.

CMB.TECH is headquartered in Antwerp, Belgium, and has offices across Europe, Asia, United States and Africa.

CMB.TECH is listed on Euronext Brussels and the NYSE under the ticker symbol “CMBT” and on Euronext Oslo Børs under the ticker symbol “CMBTO”.

More information can be found at https://cmb.tech

Forward-Looking Statements

Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbour protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts. The Company desires to take advantage of the safe harbour provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbour legislation. The words “believe”, “anticipate”, “intends”, “estimate”, “forecast”, “project”, “plan”, “potential”, “may”, “should”, “expect”, “pending” and similar expressions identify forward-looking statements.

The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, our management’s examination of historical operating trends, data contained in our records and other data available from third parties. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that we will achieve or accomplish these expectations, beliefs or projections.

In addition to these important factors, other important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include the failure of counterparties to fully perform their contracts with us, the strength of world economies and currencies, general market conditions, including fluctuations in charter rates and vessel values, changes in demand for tanker vessel capacity, changes in our operating expenses, including bunker prices, dry-docking and insurance costs, the market for our vessels, availability of financing and refinancing, charter counterparty performance, ability to obtain financing and comply with covenants in such financing arrangements, changes in governmental rules and regulations or actions taken by regulatory authorities, potential liability from pending or future litigation, general domestic and international political conditions, potential disruption of shipping routes due to accidents or political events, vessels breakdowns and instances of off-hires and other   factors. Please see our filings with the United States Securities and Exchange Commission for a more complete discussion of these and other risks and uncertainties.

This information is published in accordance with the requirements of the Continuing Obligations on Euronext Oslo Børs.

Condensed consolidated interim statement of financial position (unaudited)

(in thousands of USD)

             
      December 31, 2025     December 31, 2024
ASSETS            
             

Non-current assets
           
Vessels             6,323,773     2,617,484
Assets under construction             738,298     628,405
Right-of-use assets             4,847     1,910
Other tangible assets             23,981     21,628
Prepayments             1,075     1,657
Intangible assets             12,710     16,187
Goodwill             177,022    
Receivables             98,618     75,076
Investments             111,346     61,806
Deferred tax assets             2,850     10,074
             
Total non-current assets     7,494,520     3,434,227
             

Current assets
           
Inventory             77,175     26,500
Trade and other receivables             319,341     235,883
Current tax assets             4,912     3,984
Cash and cash equivalents             146,529     38,869
      547,957     305,236
             
Non-current assets held for sale             363,097     165,583
             
Total current assets     911,054     470,819
             
TOTAL ASSETS     8,405,574     3,905,046
             
             
EQUITY and LIABILITIES            
             

Equity
           
Share capital             343,440     239,148
Share premium             1,817,557     460,486
Translation reserve             9,502     (2,045)
Hedging reserve             90     2,145
Treasury shares             (284,508)     (284,508)
Retained earnings             738,241     777,098
             
Equity attributable to owners of the Company     2,624,322     1,192,324
             

Non-current liabilities
           
Bank loans             2,839,590     1,450,869
Other notes             —     198,887
Other borrowings             1,876,795     667,361
Lease liabilities             3,368     1,451
Other payables             20    
Employee benefits             1,180     1,060
Deferred tax liabilities             485     438
             
Total non-current liabilities     4,721,438     2,320,066
             

Current liabilities
           
Trade and other payables             208,857     79,591
Current tax liabilities             8,288     9,104
Bank loans             351,170     201,937
Other notes             203,287     3,733
Other borrowings             286,531     95,724
Lease liabilities             1,681     2,293
Provisions             —     274
             
Total current liabilities     1,059,814     392,656
             
TOTAL EQUITY and LIABILITIES     8,405,574     3,905,046
             
             

Condensed consolidated interim statement of profit or loss (unaudited)

(in thousands of USD except per share amounts)

             
      2025     2024
      Jan. 1 – Dec. 31, 2025     Jan. 1 – Dec. 31, 2024

Shipping income
           
Revenue     1,666,223     940,246
Gains on disposal of vessels/other tangible assets     192,568     635,019
Other operating income     29,613     50,660
Total shipping income     1,888,404     1,625,925
             

Operating expenses
           
Raw materials and consumables             (10,265)             (3,735)
Voyage expenses and commissions             (362,155)     (174,310)
Vessel operating expenses             (420,409)     (199,646)
Charter hire expenses             (3,124)     (138)
Loss on disposal of vessels/other tangible assets             (4)             (2)
Depreciation tangible assets             (384,684)     (163,148)
Amortisation intangible assets             (3,284)     (2,881)
Impairment losses             (5,354)             (1,847)
General and administrative expenses     (143,284)     (77,766)
Total operating expenses     (1,332,563)     (623,473)
             
RESULT FROM OPERATING ACTIVITIES     555,841     1,002,452
             
Finance income     28,729     38,689
Finance expenses     (433,359)     (169,339)
Net finance expenses     (404,630)     (130,650)
             
Share of profit (loss) of equity accounted investees (net of income tax)             (882)     920
             
PROFIT (LOSS) BEFORE INCOME TAX     150,329     872,722
             
Income tax benefit (expense)     (10,185)     (1,893)
             
PROFIT (LOSS) FOR THE PERIOD     140,144     870,829
             

Attributable to:
           
Owners of the company     161,698     870,829
Non-controlling interest     (21,554)             —
             
Basic earnings per share     0.70     4.44
Diluted earnings per share     0.70     4.44
             
Weighted average number of shares (basic)     229,443,392     196,041,579
Weighted average number of shares (diluted)     229,443,392     196,041,579
             
             
             

Condensed consolidated interim statement of comprehensive income (unaudited)

(in thousands of USD)

             
      2025     2024
      Jan. 1 – Dec. 31, 2025     Jan. 1 – Dec. 31, 2024
             
Profit/(loss) for the period     140,144     870,829
             

Other comprehensive income (expense), net of tax
           

Items that will never be reclassified to profit or loss:
           
Remeasurements of the defined benefit liability (asset)             88             200
             

Items that are or may be reclassified to profit or loss:
           
Foreign currency translation differences     11,547     (2,280)
Cash flow hedges – effective portion of changes in fair value     (2,055)     1,005
             
Other comprehensive income (expense), net of tax     9,580     (1,075)
             
Total comprehensive income (expense) for the period     149,724     869,754
             

Attributable to:
           
Owners of the company     171,278     869,754
Non-controlling interest     (21,554)    
             
             

Condensed consolidated interim statement of changes in equity (unaudited)

  Share capital Share premium Translation reserve Hedging reserve Treasury shares Retained earnings Equity attributable to owners of the Company Non-controlling interest Total equity
                   
Balance at January 1, 2024 239,148 1,466,529 235 1,140 (157,595) 807,916 2,357,373 2,357,373
                   
Total comprehensive income (expense)         —         — (2,280) 1,005         — 871,029 869,754 869,754
                   
Total transactions with owners                  (1,006,043)                           (126,913)         (901,847) (2,034,803) (2,034,803)
                   
Balance at December 31, 2024 239,148 460,486 (2,045) 2,145 (284,508) 777,098 1,192,324 1,192,324
                   
                   
                   
  Share capital Share premium Translation reserve Hedging reserve Treasury shares Retained earnings Equity attributable to owners of the Company Non-controlling interest Total equity
                   
Balance at January 1, 2025 239,148 460,486 (2,045) 2,145 (284,508) 777,098 1,192,324 1,192,324
                   
Total comprehensive income (expense)                   11,547 (2,055)          161,786 171,278 (21,554) 149,724
                   
Total transactions with owners 104,292 1,357,071 (200,643) 1,260,720 21,554 1,282,274
                   
Balance at December 31, 2025 343,440 1,817,557 9,502 90 (284,508) 738,241 2,624,322 2,624,322
                   
                   
 

(In thousands of USD)

Condensed consolidated interim statement of cash flows (unaudited)

(in thousands of USD)

             
      2025     2024
      Jan. 1 – Dec. 31, 2025     Jan. 1 – Dec. 31, 2024
             
             
Net cash from (used in) operating activities     438,313     459,064
             
             
Net cash from (used in) investing activities     (1,621,677)     (680,230)
             
             
Net cash from (used in) financing activities     1,291,667     (172,971)
             
             
Net increase (decrease) in cash and cash equivalents     108,304     (394,137)
             
Net cash and cash equivalents at the beginning of the period     38,869             429,370
Effect of changes in exchange rates     (644)             3,636
             
Net cash and cash equivalents at the end of the period     146,529     38,869
             
             


1 Source: AXS Marine, Clarksons SIN, Breakwave Advisors, Morgan Stanley, BRS, Intermodal, Deutsche Bank, Allied, S&P Global
2 Source: AXS Marine, Clarksons SIN, IEA, Morgan Stanley, Goldman Sachs
3 Source: Clarksons SIN
4 Source: Clarksons SIN, Stolt Pool
5 Source: Clarksons Offshore, Reuters, Spinergie

Attachment



argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

$1.3 billion in fourth
quarter and $4.2 billion in full
year global product net sales, representing 90% year

over

year growth

Delivered $1.1 billion in operating income in 2025, marking first year of operating profitability

VYVGART MG label expansion supported by positive ADAPT SERON and OCULUS results; PDUFA target action date of May 10, 2026 for anti

AChR antibody

negative (“seronegative”) gMG

Management to host conference call today at 2:30 PM CET (8:30 AM ET)

February 26, 2026 7:00 AM CET

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported financial results for the full year 2025 and provided a fourth quarter business update.

In a separate press release issued today, argenx announced positive results from the Phase 3 ADAPT OCULUS study evaluating VYVGART SC pre-filled syringe (PFS) for the treatment of adult patients living with ocular myasthenia gravis (oMG). The primary endpoint was met (p=0.012), demonstrating statistically significant improvement from baseline in Myasthenia Impairment Index (MGII) Patient Reported Outcome (PRO) ocular scores at Week 4 in treated patients compared to placebo. No new safety concerns were identified.

“argenx delivered another standout year of execution in 2025,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx. “We reached 19,000 patients globally with VYVGART, expanded our impact across gMG and CIDP through the successful launch of the pre-filled syringe, and made substantial progress across our development programs, advancing the pipeline towards key milestones.”

“2026 is another year of expansion for argenx,” continued Mr. Van Hauwermeiren. “Positive data in ocular MG and the priority review of our seronegative gMG filing bring us closer to reaching even more MG patients with the broadest possible label, reinforcing our leadership in shaping the MG market. Momentum across our FcRn portfolio, including expansion into rheumatology, together with continued progress across our broader pipeline with empasiprubart, adimanebart and new first-in-class candidates from our Immunology Innovation Program, supports our next horizon of growth toward Vision 2030 and beyond.”

Strategic Priorities to Advance Vision 2030

argenx continues to advance its ‘Vision 2030’ anchored in the ambition to treat 50,000 patients globally with its medicines, secure 10 labeled indications across approved medicines, and progress five pipeline candidates into Phase 3 development by 2030.

Impact more patients globally with VYVGART

VYVGART® (IV: efgartigimod alfa-fcab and SC: efgartigimod alfa and hyaluronidase-qvfc) is a first-and-only IgG Fc-antibody fragment that targets the neonatal Fc receptor (FcRn). It is approved in three indications, including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) globally, and primary immune thrombocytopenia (ITP) in Japan. argenx is driving broad adoption as the leading precision biologic in MG and CIDP while advancing multiple label expansions.

  • Generated $1.3 billion in global product net sales in the fourth quarter and $4.2 billion for the full year 2025, representing an increase of 90% or approximately $2 billion in year-over-year growth
  • Prescription Drug User Fee Act (PDUFA) target action date for anti-acetylcholine receptor antibody negative (AChR-Ab-) gMG (MuSK+, LRP4+ and triple seronegative) is May 10, 2026
  • Positive topline results from ADAPT OCULUS support planned sBLA submission to expand VYVGART label into oMG
  • Topline results expected for primary ITP (ADVANCE-NEXT) in fourth quarter of 2026
  • Registrational studies are ongoing in two rheumatology indications
    • Topline results from ALKIVIA study evaluating autoimmune inflammatory myopathies (AIM or myositis) expected in third quarter of 2026
    • Topline results from UNITY study (Sjogren’s disease) expected in second half of 2027
  • Registrational study in Graves’ disease (GD) expected to initiate in 2026, expanding development into thyroid-driven autoimmunity

Shape the long-term future of FcRn medicines

argenx is focused on shaping the long-term future of FcRn medicines by advancing new pipeline candidates, innovative delivery modalities, and combination approaches to set new standards for patients.

  • VYVGART SC autoinjector expected to launch in 2027
  • ADAPT-Forward combination study ongoing to evaluate empasiprubart as an add on therapy to efgartigimod
  • Progressing two next‑generation FcRn candidates in 2026: ARGX‑213 expected to enter patient studies and ARGX‑124 expected to complete Phase 1

Deliver next wave of immunology innovation

By the end of 2026, the argenx pipeline will include four Phase 3 molecules and a total of 10 molecules in clinical development. Empasiprubart (anti-C2) is in Phase 3 for MMN and CIDP and adimanebart (MuSK agonist) will enter Phase 3 for congenital myasthenic syndromes (CMS). ARGX-121 (anti-IgA) and ARGX-109 (anti-IL-6) are both entering patient studies this year. Three additional molecules from the IIP are expected to enter Phase 1 in 2026, supporting argenx’s goal of launching, on average, one new pipeline candidate each year.

Empasiprubart

  • Topline results from EMPASSION study (MMN) expected in fourth quarter of 2026
  • Topline results from EMVIGORATE and EMNERGIZE studies (CIDP) expected in second half of 2027
  • Decision for Phase 2 VARVARA study (DGF) expected mid-year 2026 to complete 52-week efficacy analysis

Adimanebart

  • CMS registrational study on track to start in third quarter of 2026
  • Topline Phase 2a data from amyotrophic lateral sclerosis (ALS) study does not support continued development

Earlier-stage Programs

  • Phase 2 study of ARGX-121 in IgA nephropathy (IgAN) expected to start in 2026
  • Three new first-in-class molecules are on track to enter Phase 1 in 2026, including ARGX‑118 (Galectin‑10 inhibitor), ARGX‑125 (bispecific antibody), and TSP‑101, the Fn14‑targeting program from the Tensegrity research collaboration

FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

argenx SE

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS

    Three Months Ended   Twelve Months Ended
    December 31   December 31
(in thousands of $ except for per share data)   2025   2024   2025     2024
Product net sales   $         1,285,711           $         736,968           $         4,151,316           $         2,185,883        
Other operating income*             36,444                     24,252                     96,734                     66,156        
Total operating income             1,322,155                     761,220                     4,248,050                     2,252,039        
                         
Cost of sales   $         (149,687)   $         (72,656)   $         (450,665)   $         (227,289)
Research and development expenses             (371,714)             (297,228)             (1,364,132)             (983,423)
Selling, general and administrative expenses             (429,616)             (285,945)             (1,367,057)             (1,055,337)
Loss from investment in a joint venture             (3,527)             (2,350)             (12,390)             (7,644)
Total operating expenses             (954,544)             (658,179)             (3,194,244)             (2,273,693)
                         
Operating profit/(loss)   $         367,611           $         103,041           $         1,053,806           $         (21,654)
                         
Financial income   $         44,874           $         39,095           $         163,091           $         157,509        
Financial expense             (828)             (704)             (4,082)             (2,464)
Exchange (losses)/gains             (8,363)             (54,923)             65,792                     (48,211)
                         
Profit for the period before taxes   $         403,294           $         86,509           $         1,278,607           $         85,180        
Income tax benefit   $         129,656           $         687,652           $         13,428           $         747,860        
Profit for the period   $         532,950           $         774,161           $         1,292,035           $         833,040        
Profit for the period attributable to:                        
Owners of the parent   $         532,950           $         774,161           $         1,292,035           $         833,040        
Weighted average number of shares outstanding used for basic profit per share             61,732,177                     60,517,968                     61,294,149                     59,855,585        
Basic profit per share (in $)   $         8.63           $         12.79           $         21.08           $         13.92        
Weighted average number of shares outstanding used for diluted profit per share             66,428,415                     65,661,428                     66,029,215                     65,177,815        
Diluted profit per share (in $)   $         8.02           $         11.79           $         19.57           $         12.78        

*Comparative figures have been presented to be consistent with the one adopted in the current period with respect to the combination of collaboration revenue and other operating income.

DETAILS OF THE FINANCIAL RESULTS

Total operating income for the three and twelve months ended December 31, 2025 was $1.3 billion and $4.2 billion, respectively, compared to $0.8 billion and $2.3 billion, respectively, for the same periods in 2024, and mainly consisted of:

  • Product net sales of VYVGART for the three and twelve months ended December 31, 2025 were $1.3 billion and $4.2 billion, respectively, compared to $0.7 billion and $2.2 billion, respectively, for the same periods in 2024.
  • Other operating income for the three and twelve months ended December 31, 2025 was $36 million and $97 million, respectively, compared to $24 million, and $66 million, respectively, for the same periods in 2024. The other operating income primarily relates to research and development tax incentives and payroll tax rebates.

Total operating expenses for the three and twelve months ended December 31, 2025 were $1.0 billion and $3.2 billion, respectively, compared to $0.7 billion and $2.3 billion, respectively, for the same periods in 2024, and mainly consisted of:

  • Cost of sales for the three and twelve months ended December 31, 2025 was $150 million and $451 million, respectively, compared to $73 million and $227 million, respectively, for the same periods in 2024. The cost of sales was recognized with respect to the sale of VYVGART.
  • Research and development expenses for the three and twelve months ended December 31, 2025 were $0.4 billion and $1.4 billion, respectively, compared to $0.3 billion and $1.0 billion, respectively, for the same periods in 2024. The expenses mainly related to:

    • Advancing efgartigimod across multiple severe autoimmune indications;
    • Progressing empasiprubart into multiple indications;
    • Executing studies for adimanebart in rare neuromuscular diseases; and
    • Early-stage discovery and preclinical programs to sustain long-term pipeline growth
  • Selling, general and administrative expenses for the three and twelve months ended December 31, 2025 were $0.4 billion and $1.4 billion, respectively, compared to $0.3 billion and $1.1 billion, respectively, for the same periods in 2024. The selling, general and administrative expenses mainly related to professional and marketing fees linked to global commercialization of the VYVGART franchise, and personnel expenses.

Financial income for the three and twelve months ended December 31, 2025 was $45 million and $163 million, respectively, compared to $39 million and $158 million, respectively, for the same periods in 2024.

Income tax benefit

    Three Months Ended   Twelve Months Ended
    December 31   December 31
(in millions of $)   2025   2024   2025     2024
Current tax expense   $         (216)             (25)             (338)             (54)
Deferred tax benefit             346                     713                     351                     802        
Income tax benefit   $         130                     688                     13                     748        

Profit for the three and twelve month periods ended December 31, 2025 was $533 million and $1.3 billion, respectively, compared to $774 million and $833 million, respectively, for the same periods in 2024. On a per weighted average share basis, the basic profit per share was $21.08 for the year ended December 31, 2025, compared to $13.92 for the year ended December 31, 2024.

EXPECTED 2026 FINANCIAL CALENDAR

  • March 19, 2026: Publication of the 2025 Annual Report
  • May 6, 2026: Annual General Meeting of Shareholders in Amsterdam, the Netherlands
  • May 7, 2026: First Quarter 2026 Financial Results and Business Update
  • July 23, 2026: Half Year and Second Quarter 2026 Financial Results and Business Update
  • October 22, 2026: Third Quarter 2026 Financial Results and Business Update

CONFERENCE CALL DETAILS

The full year 2025 financial results and business update will be discussed during a conference call and webcast presentation today at 2:30 pm CET/8:30 am ET. A webcast of the live call and replay may be accessed on the Investors section of the argenx website at argenx.com/investors.

Dial-in numbers:

Please dial in 15 minutes prior to the live call.

Belgium 32 800 50 201
France 33 800 943355
Netherlands 31 20 795 1090
United Kingdom 44 800 358 0970
United States 1 888 415 4250
Japan 81 3 4578 9081
Switzerland 41 43 210 11 32

About VYVGART

VYVGART® (efgartigimod alfa fcab) is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG autoantibodies. It is the first approved FcRn blocker for the treatment of generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) globally, and for primary immune thrombocytopenia (ITP) in Japan. VYVGART SC is a subcutaneous combination of efgartigimod alfa and recombinant human hyaluronidase PH20 (rHuPH20), Halozyme’s ENHANZE® drug delivery technology to facilitate subcutaneous injection delivery of biologics. It is marketed as VYVGART® Hytrulo in the U.S., VYVGART SC in Europe, VYVDURA® in Japan, and may be marketed under different proprietary names following approval in other regions.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit  www.argenx.com  and follow us on LinkedInInstagramFacebook, and YouTube.

Media:

Ben Petok
[email protected]

Investors:

Alexandra Roy
[email protected]

Forward Looking Statements

The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements.” These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “advance,” “commit,” “continue,” “expand,” “expect,” and “progress,” and include statements argenx makes concerning its belief that 2026 is a year of expansion for the Company; its goal to expand the use of VYVGART to the broadest possible label to reach even more MG patients;  its growth due to its momentum across its FcRn portfolio, together with continued progress across its broader pipeline with empasiprubart, adimanebart and new first-in-class candidates from its Immunology Innovation Program; its continued advancement of its ‘Vision 2030’ anchored in the ambition to treat 50,000 patients globally with its medicines, secure 10 labeled indications across approved medicines, and progress five pipeline candidates into Phase 3 development by 2030; the filing of the sBLA for oMG; the expected timing of topline results expected for primary ITP (ADVANCE-NEXT) in fourth quarter of 2026; the expected timing of its ongoing registrational studies in two rheumatology indications: (1) topline results from ALKIVIA study evaluating autoimmune inflammatory myopathies (AIM or myositis) expected in third quarter of 2026 and (2) topline results from UNITY study (Sjogren’s disease) expected in second half of 2027; the expected timing of the registrational study in Graves’ disease (GD) expected to initiate in 2026; its advancement of new pipeline candidates, innovative delivery modalities and combination approaches to set new standards for patients, including the expected timing of: (1) VYVGART SC autoinjector expected to launch in 2027; and (2) the progression of two next-generation FcRn candidates in 2026: ARGX-213 expected to enter patient studies and ARGX-124 expected to complete Phase 1; its expectation that by the end of 2026, the argenx pipeline will include four Phase 3 molecules and a total of 10 molecules in clinical development, including: (1) Empasiprubart (anti-C2) in Phase 3 for MMN and CIDP; (2) adimanebart (MuSK agonist) entering Phase 3 for congenital myasthenic syndromes (CMS); (3) ARGX-121 (anti-IgA) and ARGX-109 (anti-IL-6) both entering patient studies this year; and (4) three additional molecules from the IIP entering Phase 1 in 2026, supporting argenx’s goal of launching, on average, one new pipeline candidate each year; the expected timing of its empasiprubart topline results from (1) EMPASSION study (MMN) in fourth quarter of 2026 and (2) EMVIGORATE and EMNERGIZE studies (CIDP) in second half of 2027; the expected timing of the decision for empasiprubart Phase 2 VARVARA study (DGF) at mid-year 2026 to complete 52-week efficacy analysis; the expected timing of the adimanebart CMS registrational study to start in third quarter of 2026; the expected timing of its clinical studies for its earlier-stage programs, including (1) Phase 2 study of ARGX-121 in IgA nephropathy (IgAN) to start in 2026 and (2) three new first-in class molecules to enter Phase 1 in 2026, including ARGX-118 (Galectin-10 inhibitor), ARGX-125 (bispecific antibody), and TSP-101, the Fn14-targeting program from the Tensegrity research collaboration; its expected 2026 financial calendar,; its commitment to improve the lives of people suffering from severe autoimmune diseases; and its aim to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx’s actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including but not limited to, the results of argenx’s clinical trials; expectations regarding the inherent uncertainties associated with the development of novel drug therapies; preclinical and clinical trial and product development activities and regulatory approval requirements; the acceptance of its products and product candidates by its patients as safe, effective and cost-effective; the impact of governmental laws and regulations, including tariffs, export controls, sanctions and other regulations on its business; its reliance on third-party suppliers, service providers and manufacturers; inflation and deflation and the corresponding fluctuations in interest rates; and regional instability and conflicts. A further list and description of these risks, uncertainties and other risks can be found in argenx’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx’s most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.



Molecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha Radiotherapeutics

Partnership with leading nuclear medicine specialist enables advancing pipeline of wholly-owned Radio-DARPin therapeutics for imaging and therapeutic radio-isotopes, including Actinium-225 (225Ac)

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) — Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it has entered into an agreement with Eckert & Ziegler, leading specialist in isotope-related components for nuclear medicine and radiation therapy, to enable the development and manufacturing of Radio-DARPin therapeutics.

“We are pleased to work with Eckert & Ziegler, a global leader in radiopharmaceutical manufacturing. This agreement will expand the potential of Radio-DARPins as vectors for precise delivery of therapeutic alpha-emitting isotopes to tumors, now including Actinium-225, in addition to Lead-212 through our long-term strategic partnership with Orano Med,” said Alexander Zürcher, COO of Molecular Partners. He added: “The promise of Radio-DARPins is underlined by the progress of our lead candidate MP0712, targeting DLL3, having just opened the Phase 1/2a trial for the treatment of patients with small cell lung cancer (SCLC)”. 

Under the non-exclusive agreement, Eckert & Ziegler will support Molecular Partners with a comprehensive range of services covering development activities for Radio-DARPins with Actinium-225 (225Ac) and Lutetium-177 (177Lu) payloads. The development agreement will leverage Eckert & Ziegler’s state-of-the-art laboratories, including its newly established Alpha Laboratory in Berlin, Germany, dedicated exclusively to work with alpha emitters.

For its growing Radio-DARPin pipeline, Molecular Partners is evaluating various radio-nuclides to tailor Radio-DARPin candidates to patient needs – matching vector and isotope properties with target and disease biology. The Company plans to present pre-clinical data on Radio-DARPins’ suitability with multiple isotopes at the 3rd Global Radiopharmaceuticals Development Summit in March 2026 in Shanghai, China.

Eckert & Ziegler is a globally leading specialist for isotope-related components in nuclear medicine and radiation therapy, offering a broad range of services and products from early development work to contract manufacturing and distribution.

“Supporting highly innovative companies such as Molecular Partners in developing their promising technology platforms is a key objective of our group,” said Dr. Harald Hasselmann, CEO of Eckert & Ziegler. “Bringing together our expertise in isotopes, radiochemistry and development infrastructure with our partners’ innovations will enable patients worldwide to benefit from new treatments in the future.”

About Radio-DARPins

Molecular Partners’ Radio-DARPins are designed as ideal vectors for precise delivery of potent alpha-emitting isotopes to tumor lesions and have the potential to unlock a broad range of tumor targets for targeted radiopharmaceuticals. Building on the DARPins’ unique properties, Molecular Partners has developed a proprietary Radio-DARPin platform to address historic limitations of radioligand therapy, such as kidney accumulation and toxicity, and suboptimal tumor uptake. Molecular Partners’ Radio-DARPins addresses these limitations through half-life extension technologies and surface engineering approaches, while preserving the advantages of the small protein format.

About DARPin Therapeutics

DARPin (Designed Ankyrin Repeat Protein) therapeutics are a novel class of protein drugs based on natural binding proteins, which have been clinically-validated across several therapeutic areas and developed through to the registrational stage. The key properties of DARPins – intrinsic potential for high affinity and specificity, as well as small size, flexible architecture, and high stability – offer unmatched advantages to drug design, such as multispecificity, broad target range, and tunable half-life. The Company’s Radio-DARPins enable highly effective and specific delivery of potent radioactive payloads to tumor lesions while sparing healthy tissues. Molecular Partners’ Switch-DARPins allow conditional, tumor-localized immune activation, which enables increased safety and potency for next-generation immune cell engagers. Powered by twenty years of DARPin leadership, Molecular Partners has built an innovative, rapid and cost-effective DARPin drug design engine, including proprietary DARPin libraries and platforms, for candidates produced with optimized properties and tailored to therapeutic needs.

About Molecular Partners AG 
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering a novel class of protein drugs known as DARPin therapeutics, for medical challenges other treatment modalities cannot readily address. Molecular Partners leverages the key properties of DARPins to design and develop differentiated therapeutics for cancer patients, including targeted radiopharmaceuticals and next-generation immune cell engagers. The Company has proprietary programs in various stages of pre-clinical and clinical development, as well as programs developed through partnerships with leading pharmaceutical companies and academic centers. Molecular Partners, founded in 2004, has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit www.molecularpartners.com and find us on LinkedIn and Twitter / X @MolecularPrtnrs

For further details, please contact:

Molecular Partners
Seth Lewis, SVP Investor Relations & Strategy
Concord, Massachusetts, U.S.
[email protected]
Tel: +1 781 420 2361

Laura Jeanbart, PhD, Head of Portfolio Management & Communications
Zurich-Schlieren, Switzerland
[email protected]
Tel: +41 44 575 19 35

Eckert & Ziegler SE
Jan Schöpflin, Marketing / Karolin Riehle, Investor Relations
[email protected][email protected]
Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners’ current or future product candidates; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners’ product candidates and its RDT and Switch-DARPin platforms; the selection and development of future programs; Molecular Partners’ collaboration with Orano Med including the benefits and results that may be achieved through the collaboration; and Molecular Partners’ expected business and financial outlook, including anticipated expenses and cash utilization for 2026 and its expectation of its current cash runway. These statements may be identified by words such as “aim”, “anticipate”, “expect”, “guidance”, “intend”, “outlook”, “plan”, “potential”, “will” and similar expressions, and are based on Molecular Partners’ current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners’ expectations include its plans to develop and potentially commercialize its product candidates; Molecular Partners’ reliance on third party partners and collaborators over which it may not always have full control; Molecular Partners’ ongoing and planned clinical trials and preclinical studies for its product candidates, including the timing of such trials and studies; the risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with future clinical trials; the timing of and Molecular Partners’ ability to obtain and maintain regulatory approvals for its product candidates; the extent of clinical trials potentially required for Molecular Partners’ product candidates; the clinical utility and ability to achieve market acceptance of Molecular Partners’ product candidates; the potential that Molecular Partners’ product candidates may exhibit serious adverse, undesirable or unacceptable side effects; the impact of any health pandemic, macroeconomic factors and other global events on Molecular Partners’ preclinical studies, clinical trials or operations, or the operations of third parties on which it relies; Molecular Partners’ plans and development of any new indications for its product candidates; Molecular Partners’ commercialization, marketing and manufacturing capabilities and strategy; Molecular Partners’ intellectual property position; Molecular Partners’ ability to identify and in-license additional product candidates; unanticipated factors in addition to the foregoing that may cause Molecular Partners’ actual results to differ from its financial and business projections and guidance; and other risks and uncertainties set forth in Molecular Partners’ Annual Report on Form 20-F for the year ended December 31, 2024 and other filings Molecular Partners makes with the SEC from time to time. These documents are available on the Investors page of Molecular Partners’ website at www.molecularpartners.com. In addition, this press release contains information relating to interim data as of the relevant data cutoff date, results of which may differ from topline results that may be obtained in the future. Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.



Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) — Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced its attendance and presentations at upcoming investor conferences.

Molecular Partners will also issue its full-year 2025 financial report, along with its Annual Report, on March 12, 2026.

Details of the events:

TD Cowen 46th Annual Health Care Conference

Boston, MA, March 2-4, 2026
Molecular Partners CEO Patrick Amstutz will take part in a fireside chat on Monday, March 2 at 2.30-3.00 pm ET (8.30-9.00 pm CET).

Leerink Partners Global Healthcare Conference 2026

Miami, FL, March 9-11 March, 2026
Molecular Partners CEO Patrick Amstutz will take part in a fireside chat on Monday, March 9 at 4.20-4.50 pm EDT (9.20-9.50 pm CET).

Full Year 2025 Financial Results Announcement

Thursday, March 12, 2026 at 4.00 pm EDT (9.00 pm CET).

Both fireside chats will be made available on the Company’s website under the investor section.

About Molecular Partners AG 
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering a novel class of protein drugs known as DARPin therapeutics, for medical challenges other treatment modalities cannot readily address. Molecular Partners leverages the key properties of DARPins to design and develop differentiated therapeutics for cancer patients, including targeted radiopharmaceuticals and next-generation immune cell engagers. The Company has proprietary programs in various stages of pre-clinical and clinical development, as well as programs developed through partnerships with leading pharmaceutical companies and academic centers. Molecular Partners, founded in 2004, has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit www.molecularpartners.com and find us on LinkedIn and Twitter / X @MolecularPrtnrs

For further details, please contact:

Seth Lewis, SVP Investor Relations & Strategy
Concord, Massachusetts, U.S.
[email protected]
Tel: +1 781 420 2361

Laura Jeanbart, PhD, Head of Portfolio Management & Communications
Zurich-Schlieren, Switzerland
[email protected]
Tel: +41 44 575 19 35

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners’ current or future product candidates; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners’ product candidates and its RDT and Switch-DARPin platforms; the selection and development of future programs; Molecular Partners’ collaboration with Orano Med including the benefits and results that may be achieved through the collaboration; and Molecular Partners’ expected business and financial outlook, including anticipated expenses and cash utilization for 2026 and its expectation of its current cash runway. These statements may be identified by words such as “aim”, “anticipate”, “expect”, “guidance”, “intend”, “outlook”, “plan”, “potential”, “will” and similar expressions, and are based on Molecular Partners’ current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners’ expectations include, but are not limited to, those set forth in under the heading “Risk Factors” in Molecular Partners’ Annual Report on Form 20-F for the year ended December 31, 2024 and other filings Molecular Partners makes with the SEC from time to time. These documents are available on the Investors page of Molecular Partners’ website at www.molecularpartners.com.

Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.​



Faraday Future to Kick Off 2026 EAI Robotics Deliveries Beginning Feb. 27 by Delivering to an Airbnb Operator; Establishes First U.S. “EAI Robot & Vehicle + Vacation Rental” Deployment

Faraday Future to Kick Off 2026 EAI Robotics Deliveries Beginning Feb. 27 by Delivering to an Airbnb Operator; Establishes First U.S. “EAI Robot & Vehicle + Vacation Rental” Deployment

  • The delivery on February 27 will mark the beginning of the Company’s FF EAI Robotics deliveries, which will include high-end consumer sectors along with the exploration of additional “EAI Robot & Vehicle +” application scenarios across the U.S.

  • The initial batch of deliveries to Golden Hills Investment LLC, a Florida-based high-end vacation rental investor and operator, marks a unique usage through a “EAI Robot & Vehicle + Vacation Rental” commercial application.

LOS ANGELES–(BUSINESS WIRE)–
Faraday Future Intelligent Electric Inc. (Nasdaq: FFAI) (“Faraday Future,” “FF,” or the “Company”), a California-based global Embodied AI (EAI) ecosystem company, today announced its kick-off plans for its first EAI Robotics deliveries, just weeks after the Company announced its entry into the growing robotics industry. Its first deliveries are scheduled for February 27 to Golden Hills Investment LLC, a Florida-based high-end vacation rental investor and operator. This will not only mark FF’s first EAI Robot delivery but also mark a unique opportunity for FF to establish its robots within a consumer short-term rental application scenario. This milestone for FF marks a significant step toward becoming the first company in the U.S. market to achieve deliveries of EAI robots.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225850179/en/

Faraday Future to Kick Off 2026 EAI Robotics Deliveries Beginning Feb. 27 by Delivering to an Airbnb Operator; Establishes First U.S. “EAI Robot & Vehicle + Vacation Rental” Deployment

Faraday Future to Kick Off 2026 EAI Robotics Deliveries Beginning Feb. 27 by Delivering to an Airbnb Operator; Establishes First U.S. “EAI Robot & Vehicle + Vacation Rental” Deployment

The Company will provide additional details on the delivery ceremony and its strategic significance in the Co-CEO Weekly Report and press release on March 1st. Golden Hills Investment LLC is a short-term vacation rental operator in Florida and Nevada. Golden Hills will become the first purchaser of FF EAI Robotics.

Following deployment, the FF EAI robots will deliver both functional and experiential value to guests staying at some of Golden Hills’ premium vacation properties. This integration is expected to not only enhance the overall operating performance of Golden Hills’ luxury rental portfolio, but also to improve market exposure and sales conversion for FF EAI Robotics within real-world usage scenarios.

This collaboration further advances FF’s “EAI Robot & Vehicle +” ecosystem integration and establishes a commercial model. It represents the first deployment of EAI Robotics within the shared living industry and introduces a new global commercial application scenario for EAI in hospitality environments. The Company intends to accelerate rollout in this sector and scale real-world deployment in 2026, laying the foundation for broader industry expansion.

ABOUT FARADAY FUTURE

Faraday Future is a California-based global intelligent Company founded in 2014 and is dedicated to reshaping the future of mobility through vehicle electrification, intelligent technologies, and AI innovation. Its flagship vehicle, the FF 91, began deliveries in 2023 and reflects the brand’s pursuit of ultra-luxury, cutting-edge technology, and high performance. FF’s second brand, FX, targets the high-volume mainstream vehicle market. Its first model, Super One, is positioned as a first-class EAI-MPV, with deliveries planned to begin in 2026. FF recently announced its entry into the Embodied AI Robotics business with sales beginning this year, connecting its future strategy of bringing a new era of EAI vehicles and EAI robotics. For more information, please visit https://www.ff.com/

FORWARD LOOKING STATEMENTS

This press release includes “forward looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words “plan to,” “can,” “will,” “should,” “future,” “potential,” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements, which include statements regarding FF’s entry into the embodied AI robotics market, involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company’s control, which could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements.

Important factors, that may affect actual results or outcomes include, among others: demand for our robotics products; competition in the robotics industry, which includes companies with far superior experience, funding and name recognition; our reliance on a single OEM for robotics products; our ability to get the planned robotics products to comply with all applicable U.S. rules and regulations; the ability of the robotics OEM to timely supply robotics to the Company; tariff uncertainty for products imported products, particularly China; demand from automobile dealers for robotics products; the Company’s ability to maintain its listing on Nasdaq; the availability of sufficient share capital to execute on its strategy, which the Company currently lacks; the agreement of stockholders to substantially increase the Company’s share capital, which could result in substantial additional dilution; the Company’s ability to homologate FX vehicles for sale; the Company’s ability to secure the necessary funding to execute on the FX strategy, which will be substantial; the Company’s ability to secure an occupancy certificate for its Hanford facility; the Company’s ability to continue as a going concern and improve its liquidity and financial position; the Company’s ability to pay its outstanding obligations; the Company’s ability to remediate its material weaknesses in internal control over financial reporting and the risks related to the restatement of previously issued consolidated financial statements; the Company’s limited operating history and the significant barriers to growth it faces; the Company’s history of losses and expectation of continued losses; the success of the Company’s payroll expense reduction plan; the Company’s ability to execute on its plans to develop and market its vehicles and the timing of these development programs; the Company’s estimates of the size of the markets for its vehicles and cost to bring those vehicles to market; the rate and degree of market acceptance of the Company’s vehicles; the Company’s ability to cover future warranty claims; the success of other competing manufacturers; the performance and security of the Company’s vehicles; current and potential litigation involving the Company; the Company’s ability to receive funds from, satisfy the conditions precedent of and close on the various financings described elsewhere by the Company; the result of future financing efforts, the failure of any of which could result in the Company seeking protection under the Bankruptcy Code; the Company’s indebtedness; the Company’s ability to cover future warranty claims; the Company’s ability to use its “at-the-market” program; insurance coverage; general economic and market conditions impacting demand for the Company’s products; potential negative impacts of a reverse stock split; potential cost, headcount and salary reduction actions may not be sufficient or may not achieve their expected results; circumstances outside of the Company’s control, such as natural disasters, climate change, health epidemics and pandemics, terrorist attacks, and civil unrest; risks related to the Company’s operations in China; the success of the Company’s remedial measures taken in response to the Special Committee findings; the Company’s dependence on its suppliers and contract manufacturer; the Company’s ability to develop and protect its technologies; the Company’s ability to protect against cybersecurity risks; and the ability of the Company to attract and retain employees, any adverse developments in existing legal proceedings or the initiation of new legal proceedings, and volatility of the Company’s stock price. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s Form 10-K filed with the SEC on March 31, 2025, and Form 10-Qs for the quarters ended June 30, 2025 and September 30, 2025 filed with the SEC on May 9, 2025, August 19, 2025 and November 21, 2025, respectively, and other documents filed by the Company from time to time with the SEC.

Investors (English): [email protected]

Investors (Chinese): [email protected]

Media: [email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Robotics Automotive EV/Electric Vehicles Technology Alternative Vehicles/Fuels Artificial Intelligence Hardware

MEDIA:

Photo
Photo
Faraday Future to Kick Off 2026 EAI Robotics Deliveries Beginning Feb. 27 by Delivering to an Airbnb Operator; Establishes First U.S. “EAI Robot & Vehicle + Vacation Rental” Deployment
Logo
Logo

argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis

  • Study met primary endpoint (p-value = 0.012)

  • First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG

  • Results support planned Supplemental Biologics License Application (sBLA) submission to U.S. Food and Drug Administration (FDA) to expand label into oMG

Regulated Information – Inside Information 

February 26, 2026, 6:30 AM CET
  

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART® (efgartigimod alfa and hyaluronidase-qvfc) in adults with ocular myasthenia gravis (oMG).

ADAPT OCULUS met its primary endpoint (p-value=0.012), showing that patients living with oMG and treated with VYVGART demonstrated statistically significant improvement from baseline in Myasthenia Impairment Index (MGII) Patient Reported Outcome (PRO) ocular scores at Week 4 compared to placebo. In the overall population, mean change from baseline in patients treated with VYVGART was a 4.04 point improvement in MGII PRO versus a mean change of 1.99 MGII PRO score in patients treated with placebo. Patients treated with VYVGART experienced a marked reduction of key ocular symptoms: diplopia (double vision) and ptosis (drooping of the upper eyelids).

“Ocular myasthenia gravis significantly impacts patients’ daily lives, affecting vision, independence and the ability to do routine tasks, such as work or drive a car. Yet today, there are no approved targeted medicines for this disease,” said Carolina Barnett-Tapia, M.D., Ph.D., Associate Professor of Medicine (Neurology) at the University of Toronto. “The improvements observed with VYVGART in the OCULUS trial offer hope to the thousands of myasthenia gravis patients with ocular involvement.”

VYVGART was well tolerated and had a favorable safety profile in patients with oMG, consistent with prior studies. No new safety concerns were identified.

“ADAPT OCULUS is the first registrational study specifically designed to evaluate a targeted therapy for ocular myasthenia gravis,” said Luc Truyen, M.D., Ph.D., Chief Medical Officer of argenx. “Ocular MG has been historically under-studied and represents a significant unmet need in the MG community. These positive results deliver on our patient-centered approach to drug development and bring us one step closer to our vision of delivering a targeted, transformative treatment option to as many MG patients as possible and ensuring no patient is left behind.”

Data from the ADAPT OCULUS study will be presented at an upcoming medical meeting.

About the ADAPT OCULUS Study Design

ADAPT OCULUS is a Phase 3, randomized, double-blind, placebo-controlled, parallel-group design study evaluating the efficacy and safety of VYVGART SC administered by prefilled syringe in adult patients with ocular MG (MGFA Class I) (n=141) across North America, Europe and Asia-Pacific. In Part A, randomized participants (1:1) received four once-weekly injections of efgartigimod PH20 SC or placebo PH20 SC followed by a 4-week follow-up. In Part B, open-label extension, participants received 2 cycles of four once-weekly efgartigimod injections with a 4-week interval between cycles. Additional cycles from Cycle 3 onward could start ≥1 week after the last administration of the previous cycle, based on clinical status.

The primary endpoint was the change from baseline in Myasthenia Gravis Impairment Index (MGII) (patient-reported outcome [PRO] subcomponent) ocular score at week 4 (day 29) compared to placebo in Part A. Enrolled participants were either seropositive or seronegative for AChR-Ab, and MGFA Class I with only ocular muscle weakness as determined by an MGII (PRO) ocular score of ≥6 with at least 2 ocular items with a score of ≥2. Participants were on a stable dose of gMG treatment prior to randomization, including acetylcholinesterase inhibitors, corticosteroids or nonsteroidal immunosuppressive drugs.

MGII is a validated measure of disease severity based on the signs and symptoms of myasthenia gravis and includes an ocular-specific subdomain that evaluates the two key clinical symptoms of oMG: diplopia and ptosis.

Important Safety Information  

What is VYVGART

®


(efgartigimod alfa-fcab)? 

VYVGART is a prescription medicine used to treat a condition called generalized myasthenia gravis, which causes muscles to tire and weaken easily throughout the body, in adults who are positive for antibodies directed toward a protein called acetylcholine receptor (anti-AChR antibody positive). 
  
IMPORTANT SAFETY INFORMATION 
Do not use VYVGART if you have a serious allergy to efgartigimod alfa or any of the other ingredients in VYVGART. VYVGART can cause serious allergic reactions and a decrease in blood pressure leading to fainting. 
  
VYVGART may cause serious side effects, including: 

  • Infection. VYVGART may increase the risk of infection. The most common infections were urinary tract and respiratory tract infections. Signs or symptoms of an infection may include fever, chills, frequent and/or painful urination, cough, pain and blockage of nasal passages/sinus, wheezing, shortness of breath, fatigue, sore throat, excess phlegm, nasal discharge, back pain, and/or chest pain. 
  • Allergic Reactions (hypersensitivity reactions). VYVGART can cause allergic reactions such as rashes, swelling under the skin, and shortness of breath. Serious allergic reactions, such as trouble breathing and decrease in blood pressure leading to fainting have been reported with VYVGART.  
  • Infusion-Related Reactions. VYVGART can cause infusion-related reactions. The most frequent symptoms and signs reported with VYVGART were high blood pressure, chills, shivering, and chest, abdominal, and back pain.

  
Tell your doctor if you have signs or symptoms of an infection, allergic reaction, or infusion-related reaction. These can happen while you are receiving your VYVGART treatment or afterward. Your doctor may need to pause or stop your treatment. Contact your doctor immediately if you have signs or symptoms of a serious allergic reaction. 
  
Before taking VYVGART, tell your doctor if you: 

  • take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines, 
  • have received or are scheduled to receive a vaccine (immunization), or 
  • have any allergies or medical conditions, including if you are pregnant or planning to become pregnant, or are breastfeeding. 

What are the common side effects of VYVGART? 

The most common side effects of VYVGART are respiratory tract infection, headache, and urinary tract infection.

These are not all the possible side effects of VYVGART. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1-800-FDA-1088. 

Please see the full



Prescribing Information



for VYVGART and talk to your doctor. 

Important Safety Information 

What is VYVGART HYTRULO® (efgartigimod alfa and hyaluronidase-qvfc)?

VYVGART HYTRULO is a prescription medicine used to treat adults with:

  • generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.
  • chronic inflammatory demyelinating polyneuropathy (CIDP).

It is not known if VYVGART HYTRULO is safe and effective in children.

IMPORTANT SAFETY INFORMATION 

Do not take VYVGART HYTRULO if you are allergic to efgartigimod alfa, hyaluronidase, or any of the ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.
  
Before taking VYVGART HYTRULO, tell your healthcare provider about all of your medical conditions, including if you:

  • have an infection or fever.
  • have recently received or are scheduled to receive any vaccinations.
  • have any history of allergic reactions.
  • have kidney (renal) problems.
  • are pregnant or plan to become pregnant. It is not known whether VYVGART HYTRULO will harm your unborn baby.
    • Pregnancy Exposure Registry. There is a pregnancy exposure registry for women who use VYVGART HYTRULO during pregnancy. The purpose of this registry is to collect information about your health and your baby. Your healthcare provider can enroll you in this registry. You may also enroll yourself or get more information about the registry by calling 1-855-272-6524 or going to VYVGARTPregnancy.com
  • are breastfeeding or plan to breastfeed. It is not known if VYVGART HYTRULO passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

VYVGART HYTRULO can cause side effects which can be serious, including:

  • Infection. VYVGART HYTRULO may increase the risk of infection. If you have an active infection, your healthcare provider should delay your treatment with VYVGART HYTRULO until your infection is gone. Tell your healthcare provider right away if you get any of the following signs and symptoms of an infection: fever, chills, frequent and painful urination, cough, pain and blockage or nasal passages, wheezing, shortness, sore throat, excess phlegm, nasal discharge.
  • Allergic reactions (hypersensitivity reactions). VYVGART HYTRULO can cause allergic reactions that can be severe. These reactions can happen during, shortly after, or weeks after your VYVGART HYTRULO injection. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction: rash, swelling of the face, lips, throat, or tongue, shortness of breath, hives, trouble breathing, low blood pressure, fainting.
  • Infusion or injection-related reactions. VYVGART HYTRULO can cause infusion or injection-related reactions. These reactions can happen during or shortly after your VYVGART HYTRULO injection. Tell your healthcare provider if you have any of the following symptoms of an infusion or injection-related reaction: high blood pressure, chills, shivering, chest, stomach, or back pain.

The most common side effects of VYVGART HYTRULO include respiratory tract infection, headache, urinary tract infection, and injection site reactions.

These are not all the possible side effects of VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see the full



Prescribing Information



for VYVGART HYTRULO and talk to your doctor. 

About VYVGART and VYVGART Hytrulo

VYVGART® (efgartigimod alfa fcab) is a first-in-class human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG autoantibodies. VYVGART® Hytrulo is a subcutaneous combination of efgartigimod alfa (VYVGART) and recombinant human hyaluronidase PH20 (rHuPH20), Halozyme’s ENHANZE® drug delivery technology to facilitate subcutaneous injection delivery of biologics. VYVGART is approved for generalized myasthenia gravis (gMG) and immune thrombocytopenia (Japan only). VYVGART Hytrulo is approved for gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART Hytrulo may be marketed under different proprietary names in other regions.

About Ocular Myasthenia Gravis (oMG)

Ocular myasthenia gravis (oMG) is a rare and chronic autoimmune disease characterized by muscle weakness limited to the muscles controlling the eyes and eyelids. Symptoms commonly include ptosis (drooping eyelids), diplopia (double vision), and fluctuating visual disturbance that can impair daily activities. Approximately 80% of myasthenia gravis (MG) patients initially present with ocular symptoms, and up to 92% experience ocular involvement at some point during the course of disease. While many progress to generalized myasthenia gravis (gMG), in 15–25% of patients, weakness remains restricted to the ocular muscles. oMG is driven by pathogenic IgG autoantibodies that disrupt communication at the neuromuscular junction. Despite the functional and quality-of-life burden associated with persistent ocular symptoms, there are currently no approved targeted therapies specifically for oMG. Treatment approaches often rely on symptomatic therapies and generalized immunosuppression, underscoring the need for additional therapeutic options for this distinct MG population.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit  www.argenx.com  and follow us on LinkedInInstagramFacebook, and YouTube.

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation (Regulation 596/2014).

Media:

Colin McBean
[email protected]

Investors:

Alexandra Roy
[email protected]

FORWARD LOOKING STATEMENTS

The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements.” These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “advance,” “commit,” “continue,” “develop,” “potential,” and “will” and include statements argenx makes concerning the potential of VYVGART for oMG patients; argenx’s vision of delivering a targeted, transformative treatment option to as many MG patients as possible; its expectation that it will submit a Supplemental Biologics License Application (sBLA) for VYVGART for oMG to the U.S. FDA by end of third quarter 2026; its commitment to improve the lives of people suffering from severe autoimmune diseases; its plan to present data from the ADAPT OCULUS study at an upcoming medical meeting; its aim to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines; its commercialization of the first approved neonatal Fc receptor (FcRn) blocker and evaluation of its broad potential in multiple serious autoimmune diseases; and its advancement of several earlier stage experimental medicines within its therapeutic franchises. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx’s actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including but not limited to, the results of argenx’s clinical trials; expectations regarding the inherent uncertainties associated with the development of novel drug therapies; preclinical and clinical trial and product development activities and regulatory approval requirements; the acceptance of its products and product candidates by its patients as safe, effective and cost-effective; the impact of governmental laws and regulations, including tariffs, export controls, sanctions and other regulations on its business; its reliance on third-party suppliers, service providers and manufacturers; inflation and deflation and the corresponding fluctuations in interest rates; and regional instability and conflicts. A further list and description of these risks, uncertainties and other risks can be found in argenx’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx’s most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.



Tigo Energy Showcases Real-time Active Commissioning Software at KEY 2026 Expo

Tigo Energy Showcases Real-time Active Commissioning Software at KEY 2026 Expo

Next-generation commissioning system designed to help streamline solar installations delivers another Total Quality Solar innovation as Tigo expands installer loyalty program

MONTEVARCHI, Italy–(BUSINESS WIRE)–Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo,” “Company”), a leading provider of intelligent solar and energy software solutions, today announced the Company’s presence as an exhibitor at the 2026 KEY – The Energy Transition Expo in Rimini, Italy, where Tigo will preview the new active commissioning software. From basic solar-only installations to advanced solar-plus-storage configurations, the system supports installers throughout the entire jobsite workflow via the Tigo EI App, delivering on-site guidance, real-time progress visibility, and clear verification of every required step to help reduce delays, truck rolls, and commissioning uncertainty. At KEY 2026, Tigo will also showcase the latest expansions to the Installer Loyalty Program, including new eligibility tiers and segments, enhanced data support for installers, and upgraded co-branding opportunities.

As Italy prepares for a new phase of structural growth in its solar market, with an estimated 6 to 8 GW of new capacity additions driven by large-scale projects, expanding self-consumption, Power Purchase Agreements (PPAs), and integrated storage, the new Tigo installation and commissioning system is designed to help installers scale with confidence. With more than twenty core enhancements to the installation and commissioning process, the new system is designed to help make solar installers more efficient. With enhanced situational awareness throughout the process, from when the system components are entered into the platform prior to arrival at the installation site, solar installers can better prepare for the work ahead.

“What sets Tigo apart is not just the breadth of its product portfolio, but the way installer feedback is systematically translated back into practical improvements on products and software,” said Luca Annovazzi, CEO at Energ.on. “From commissioning to ongoing system management, Tigo tools are clearly designed to reduce friction in the field. That translates into fewer delays, greater confidence during installation, and systems that perform as expected from day one.”

At KEY 2026, Tigo will also exhibit the latest TS-4 Flex MLPE products, designed to address the growing adoption of high-power, high-current PV modules. The new TS4-A supports modules up to 725 W and accommodates short-circuit currents up to 22A, helping to ensure compatibility with the latest-generation PV panels. In addition to module-level monitoring and rapid shutdown capabilities, Tigo TS4-A MLPE devices with optimization deployed in Italy provide more than 7.6% Reclaimed Energy on residential solar systems between 3-12kW, with up to 40% of those systems boosting energy production by more than 10%. Tigo MLPE devices are designed to maintain broad compatibility with a wide range of third-party inverters and PV modules, in line with Tigo’s mission to provide a premier technology-agnostic approach to optimization, module-level monitoring, and safety, while simplifying system design for installers across diverse project types.

“Installers play the central role in shaping how the energy transition takes form on the ground, and the more efficiently they can do their work, the more it contributes directly to the success of the solar industry at large,” Mirko Bindi, senior vice president sales EMEA and managing director Europe at Tigo Energy. “This new approach to installation and commissioning is another way in which Tigo acknowledges the installer as central to the solar industry, and we are delighted to offer these concrete benefits that reward a long-term mindset, technical expertise, and reinforce a shared commitment to high-quality installations. Lasting innovation happens when manufacturers and installers work as true partners, which is what Total Quality Solar is all about.”

Tigo representatives will be available at KEY – The Energy Transition Expo in the Rimini Exhibition Center, Booth D5.320, from March 4-6, 2026. Distribution partners will also be present at the event, showcasing the full range of Tigo solutions. To schedule a meeting with a Tigo representative to find out more about Tigo products and the benefits of the expanded installer loyalty program, visit the event page. For general inquiries, contact Tigo sales here.

About Tigo Energy

Founded in 2007, Tigo Energy, Inc. (Nasdaq: TYGO) is a worldwide leader in the development and provider of smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Tigo combines its Flex MLPE (Module Level Power Electronics) and solar optimizer technology with intelligent, cloud-based software capabilities for advanced energy monitoring and control. Tigo MLPE products maximize performance, enable real-time energy monitoring, and provide code-required rapid shutdown at the module level. The company also develops and manufactures products such as inverters and battery storage systems for the residential solar-plus-storage market. For more information, please visit www.tigoenergy.com.

Technica Communications

Luis de Leon

Email: [email protected]

KEYWORDS: Italy Europe

INDUSTRY KEYWORDS: Technology Environment Alternative Energy Green Technology Energy Software

MEDIA:

Logo
Logo